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Abstract: Treating alcohol use disorders represents a main goal in public health, but the effect of current medications is modest. Thus, in 
the last few years, research has been focusing on identifying new neuropharmacological targets for alcohol dependence. This review will 
summarize recent research, which has identified new targets to treat alcohol dependence. A variety of systems have been investigated, 
such as the endocannabinoid system, modulators of glutamatergic transmission, corticotropin-releasing factor (CRF), neuropeptide Y 
(NPY), nociceptin, glial cell line-derived neurotrophic factor (GDNF), acetaldehyde (ACD), substance P and Neurokinin 1 (NK1) recep-
tor, nicotinic acetylcholine receptors (nAchRs), alpha-adrenergic receptor, and many others. Compared to preclinical studies, only a few 
clinical studies have been conducted so far. Thus, there is a critical need to translate successful preclinical results into human clinical tri-
als. However, since some clinical studies have failed to replicate preclinical findings, future research will have not only to identify more 
efficacious medications, but also delineate the best match between a particular pharmacotherapy with a specific alcoholic subtype. 
Keywords: Alcohol dependence, neurobiology, pharmacotherapy.  
INTRODUCTION 
 Alcohol induces several neurobiological changes in the central 
nervous system (CNS). Molecular pharmacology studies demon-
strate that alcohol has only a few known primary targets, which 
include N-methyl-D-aspartic acid (NMDA), ?-aminobutyric acid 
(GABA), glycine, serotonin, nicotinic acetylcholine (Ach) recep-
tors, calcium (Ca
+2
) and potassium (K
+
) channels [1]. The initial 
exposure of alcohol to specific targets in the brain leads to the typi-
cal acute subjective psychotropic effects of this drug, ranging from 
disinhibition to sedation and even hypnosis, in parallel with in-
creased alcohol concentration. Alcohol also acts indirectly on a 
variety of neurotransmitter/neuropeptide systems including mono-
amines such as dopamine (DA), beta-endorphin, and endocannabi-
noids, and is crucial for the initiation of alcohol reinforcement and 
reward. 
 Traditionally, the activity of the mesolimbic DA system plays a 
crucial role during the initial phase of alcohol consumption re-
sponding with an increase in activity after acute alcohol challenge 
[2]. However, after chronic treatment the DA system appears to 
reduce its tonic activity [3-5] and these effects are accompanied by 
similar changes in the human brain [6,7]. Thus, it appears that a 
“normalization” of DA activity would be desirable, therapeutically 
speaking. Indeed, the “hypodopaminergic hypothesis” suggests that 
“boosting” the DA system should ameliorate compulsive 
drug/alcohol use. Chronic alcohol consumption affects virtually all 
brain neurotransmitters. These changes likely represent part of the 
pathophysiological process of alcohol dependence (AD) and con-
tribute to the compulsive use and loss of control over drinking seen 
in alcoholism. Compulsive alcohol drinking is characterized by a 
decrease in the function of the reward neurocircuitry and a recruit-
ment of antireward/stress mechanisms, with a hypertrophic cortico-
tropin-releasing factor (CRF) system and a hyperfunctional gluta-
matergic system [8]. 
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 These alcohol-induced neurobiological changes represent pos-
sible molecular targets for pharmacotherapies of alcoholism. Phar-
macotherapies for alcoholism may either modulate or block the 
rewarding effects of alcohol or stabilize neurobiological systems 
dysregulated by chronic alcohol intake, which help to facilitate 
abstinence or greatly reduce alcohol consumption. Consistent with 
these concepts, evidence is available that pharmacological treat-
ments can prolong the time to relapse following cessation of heavy 
drinking, or decrease the number of heavy drinking days [9]. 
 In the United States (US), disulfiram, naltrexone (oral and in-
jectable) and acamprosate are approved medications for the treat-
ment of AD. Several other medications (e.g. topiramate, ondanse-
tron, baclofen, and others) are also under investigation and hold 
significant promise. While other articles in this special issue  
review many of these medications [10-16] the aim of this review is 
to summarize recent research, which attempts to identify new future 
neuropharmacological targets. These novel targets may eventually 
lead to the development of new medications for AD. 
CANNABINOID RECEPTORS 
 The endocannabinoid system has an important role in the regu-
lation of the pharmacological and behavioural effects of alcohol, 
preference, drinking, and vulnerability to relapse [17-19]. 
 The main brain endocannabinoid receptor subtype, the cannabi-
noid-1 (CB1) receptor, is widely distributed in the CNS, with high 
density in the brain reward circuitry, including the ventral tegmen-
tal area (VTA) and the nucleus accumbens (NAc) [20]. Endocan-
nabinoids that activate CB1 receptors present on axon terminals of 
GABAergic neurons in the VTA act as retrograde messengers, by 
inhibiting GABA synaptic transmission, and thus removing this 
inhibitory input on dopaminergic neurons. Glutamate transmission 
from neurons of the prefrontal cortex in the VTA and NAc is simi-
larly modulated by the activation of CB1 receptors. Acute alcohol-
induced DA release in the NAc is mediated by CB1 receptors and 
chronic ethanol vapor exposure increases brain endogenous endo-
cannabinoids levels and down-regulate CB1 receptors [20-22]. 
Thus, the endocannabinoid system is involved in the rewarding 
effects of alcohol; as alcohol increases dopaminergic neuron firing 
rates, the release of endocannabinoids in the VTA further enhances 
dopaminergic activity [23]. 
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 Consistent with the evidence summarized above, enhancement 
of the CB1 receptor function increases ethanol drinking. For exam-
ple, acute administration of the CB1 receptor agonists WIN 55,212-
2 and CP 55,940, significantly stimulates voluntary ethanol intake 
in ethanol-preferring sP rats [24]. In contrast, genetic or pharmacol-
ogical blockade of the CB1 receptor decreases in ethanol consump-
tion. Several studies with CB1 receptor knock-out mice show that 
genetic CB1 receptor blockade results in a reduction in voluntary 
ethanol intake [25-29]. Pharmacological blockade with rimonabant, 
a potent, selective, and orally active blocker of the central CB1 
receptors [30] prevents habituation to ethanol drinking, when ad-
ministered at the start of exposure to alcohol in genetically-selected 
alcohol-preferring rats [31-34]. Similarly, using different animal 
models of excessive alcohol drinking in which alcohol intake was 
already established, rimonabant (administered either acutely or 
repeatedly) reduced ethanol intake [35-38], and suppressed alcohol 
self-administration [39-41]. Notably, rimonabant augmented inhibi-
tory postsynaptic potentials, revealing a tonic endocannabinoid 
activity that decreased inhibitory transmission in central amygdala 
[42]. Furthermore, experiments employing validated animal models 
for human relapse (e.g. ‘alcohol deprivation effect’, ‘reinstatement 
model’) have shown the efficacy of both rimonabant in suppressing 
relapse in alcohol-preferring animals [43-46], and surinabant, in 
preventing habituation to ethanol drinking and in showing anti-
relapse properties [47-48].  
 Two human studies testing rimonabant for alcoholism have 
been conducted. The first study was a Phase 2a, double-blind, pla-
cebo-controlled study in which 258 recently detoxified AD patients 
received a 12-week treatment with rimonabant (20 mg/d) or placebo 
[49]. This trial did not show any statistically significant difference 
between the two groups in time to first drink, time to first heavy 
drink, nor in the cumulative abstinence duration (days of absti-
nence). The second study was a Phase I/II, double-blind, placebo-
controlled laboratory study aimed at assessing the effect of rimona-
bant (20 mg/d) on alcohol consumption in 49 non-treatment seeking 
heavy alcohol drinkers [50]. In the naturalistic (outpatient) phase of 
the study, rimonabant failed to alter daily alcohol consumption. In 
the experimental (inpatient) phase of the study, after ingestion of a 
priming dose of alcohol, participants had the choice to drink up to 
an additional eight alcohol drinks or receive a small amount of 
money for each non consumed drink. Again, rimonabant did not 
significantly alter the number of alcohol drinks consumed during 
the self-administration experiment.  
 In conclusion, while animal studies suggest that the CB1 recep-
tor represents a new target for the treatment of AD, human studies 
do not demonstrate any beneficial effect of rimonabant, compared 
to placebo, on drinking outcomes. Thus, future studies are needed 
to investigate the discrepancies between animal and human studies. 
We also note that there are concerns that the medication may in-
crease depression and suicidality [51]. 
MODULATORS OF GLUTAMATERGIC TRANSMISSION 
 Glutamate is the primary excitatory neurotransmitter in the 
brain and a mediator of the synaptic plasticity required for organ-
isms to adapt behaviour to a changing environment [52,53]. Gluta-
mate, through sensitization and drug-seeking behaviours, plays a 
crucial role in the pathogenesis of alcohol and drug addiction. In 
particular, the cycle of alcohol intoxication, withdrawal, abstinence, 
and relapse induces a hyperglutamatergic state in brain regions 
associated with alcohol reward, which may contribute in increased 
alcohol intake and vulnerability to relapse in alcoholics [20]. 
 Glutamate receptors fall into one of two categories: ligand-
gated ion channels (i.e., ionotropic glutamate receptors, or iGluRs) 
and G-protein coupled receptors (i.e., metabotropic glutamate re-
ceptors, or mGluRs) [54]. Both groups of glutamate receptors seem 
to play a role in the neurobiological mechanisms on the basis of 
alcohol dependence, thus being suggested as potential targets for 
alcohol pharmacotherapy. 
 Three different types of iGluRs have been identified: the 
NMDA receptor, the ?-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA) receptor, and the kainic acid (KA) receptor. 
These receptors are ligand-gated ion channels that mediate fast 
excitatory neurotransmission [54]. Numerous preclinical studies 
show that iGluR ligands alter the reinforcing effects of drugs of 
abuse, such as ethanol, and can modify drinking behaviour [55]. 
NMDA antagonists can attenuate the alcohol deprivation effect, 
cue-induced reinstatement of alcohol-seeking behaviour, acquisi-
tion of ethanol conditioned place preference and sensitization to the 
locomotor stimulant effects of low doses of ethanol [55]. However, 
Vosler and colleagues [56] showed that NMDA antagonists, such as 
MK-801, while producing ethanol-like discriminative stimulus 
effects, did not reinstate ethanol-seeking behaviour. AMPA/KA 
receptor antagonists also attenuate operant ethanol reinforcement 
and cue-induced reinstatement in preclinical studies [55]. However, 
in some of these studies, an effect in reducing sucrose or saccharin 
reinforcement by NMDA or AMPA/KA ligands has been observed, 
thus suggesting a non selective action in reducing alcohol intake.  
 When tested in humans, the majority of iGluR antagonists had 
significant side effects, including memory loss, disorientation, and 
psychotic symptoms. Memantine is one of the few NMDA receptor 
antagonists that is generally well tolerated by humans and does not 
appear to have abuse potential [57]. Memantine is a more specific 
non-competitive NMDA receptor antagonist that has been used in 
Europe for over 20 years to treat neurological diseases. Memantine 
was approved by the Food and Drug Administration (FDA) in 2003 
for the treatment of Alzheimer’s disease. Bisaga and Evans [58] 
evaluated the acute effects of memantine (15 and 30 mg) in moder-
ate drinkers (20 drinks/week), who had no diagnosis of AD and 
were not looking for treatment. In this study, memantine (30 mg) 
reduced alcohol craving before alcohol administration. Krupitsky 
and collegues [59] evaluated the effects of memantine (20 mg/d and 
40 mg/d) on alcohol craving where alcohol craving was assessed 
before and after exposure to alcohol cues. Results of this study 
showed that memantine attenuated alcohol cue-induced craving in a 
dose-related fashion. Moreover, Krupitsky and collegues [60] also 
showed an effect of memantine 10 mg/d in reducing withdrawal 
symptoms in detoxified alcoholics However, a double-blind pla-
cebo-controlled pilot study with memantine for AD found no dif-
ferences in drinks per day and drinks per drinking day between the 
two groups [61]. Indeed, there was a significantly greater percent-
age of abstinence days in the placebo compared to the memantine 
group. 
 The anticonvulsivant levetiracetam blocks ethanol-seeking be-
haviour by inhibiting AMPA receptors [62]. An open-label study 
suggested the ability of levetiracetam to decrease alcohol with-
drawal symptoms [63]. A second open-label study testing 
levetiracetam (2000 mg/d) in 20 alcohol-dependent subjects treated 
for 10 weeks, reported a reduction in alcohol drinking, craving and 
addiction severity [64]. While double-blind placebo-controlled 
studies are needed to draw any conclusion, the preliminary evi-
dence highlights the safety of levetiracetam, when administered to 
AD individuals. 
 Given the side effects observed with the majority of iGluRs 
legands, there is interest in selective mGluRs ligands, which medi-
ate slower, modulatory glutamate neurotransmission [54]. Attenua-
tion of glutamatergic transmission by mGluRs ligands reduces the 
rewarding and reinforcing effects of ethanol as well as relapse-like 
behaviours [55]. There are eight different mGluRs, which belong to 
three groups, based on sequence similarities, preferred signal trans-
duction pathways and pharmacology. Specifically, these groups are 
Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3) 
and Group III (mGluR4, mGluR6, mGluR7, and mGluR8) [65]. 
mGluR5 and mGluR2/3 receptors are widely distributed in meso-
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corticolimbic brain regions associated with drug reinforcement. In 
particular, there is a high expression of mGluR5 in forebrain and 
limbic structures (olfactory bulb, anterior olfactory nuclei, olfactory 
tubercle, dorsal striatum, NAc, lateral septum, hippocampal forma-
tion). mGluR5s are located at both presynaptic and postsynaptic 
sites in the brain and it has been observed that the activation of 
mGluR5s interacts with ionotropic NMDA receptors, enhancing 
NMDA responses in striatal projection neurons [66]. This last ob-
servation suggests that blockade of mGluR5s could reduce glutama-
tergic transmission through NMDA receptors. Thus, blockade of 
mGluR5s could attenuate the state of hyperexcitability induced by 
glutamatergic excitatory neurotransmission during alcohol with-
drawal and abstinence, which may be associated with a high risk of 
relapse [20,67]. 
 In 1999, Gasparini and colleagues [68] published the structure 
and initial characterization of a highly potent, non-competitive 
mGlu5 receptor antagonist, the 2-methyl-6-(phenylethynyl)-
pyridine (MPEP). Later studies showed that MPEP also acts as an 
antagonist of the NMDA receptor and inhibits monoamine oxidase-
A [69]. The effects of MPEP on voluntary ethanol consumption and 
relapse behaviour were tested in preclinical studies. MPEP signifi-
cantly attenuates ethanol seeking in alcohol-preferring rats in a 
dose-related manner. Moreover, treatment with MPEP (twice a day) 
resulted in a significant dose-dependent reduction of the alcohol 
deprivation effect and to a lesser extent, of baseline drinking [70]. 
 A possible explanation for the ability of mGluR5 negative al-
losteric modulators (NAMs) to reduce ethanol self-administration is 
that mGluR5 NAMs alter the discriminative stimulus effects of 
ethanol [71]. The lack of selectivity of MPEP combined with unde-
sirable pharmacological properties (e.g. low water solubility and 
low brain penetration) led Cosford et al. [72] to develop a new 
mGlu5R antagonist, the 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-
pyridine (MTEP), which holds a greater selectivity for the mGlu5 
receptor and greater bioavailability. MTEP was tested in different 
rodent models of alcoholism and it reduced alcohol-seeking behav-
iour, decreasing both the consumption of ethanol and the appetitive 
response for ethanol [73,74]. The effects of MTEP are associated 
with regulation of cortical glutamate systems, particularly those in 
olfactory-related regions [73,74].  
 Besheer and colleagues [75] suggest that mGluR1 antagonists, 
unlike mGluR5 antagonists, do not produce alcohol-like interocep-
tive effects and do not alter the interoceptive effects produced by 
alcohol. The two receptors mGlu1 and mGlu5 are both located pri-
marily at postsynaptic sites, and share G-protein and cell signalling 
mechanisms. A functional dissociation between mGlu1 and mGlu5 
receptors in the interoceptive effects of alcohol may represent an 
explanation of the different effects of the antagonism at mGlu1 vs. 
mGlu5 receptors [75].  
 Members of the Group II mGlu receptors (mGlu2/3) have also 
emerged as potential therapeutic targets for treating alcohol AD. 
Group II agonists have anxiolytic and anticonvulsant properties and 
preclinical studies demonstrate that mGluR2/3 agonists reduce ac-
tive drug reinforcement and drug-seeking behaviour [54]. mGlu2/3 
receptors are expressed preferentially in mesocorticolimbic brain 
regions and are located both pre- and post-synaptically. Pre-
synaptic autoreceptor function is implicated in its therapeutic action 
as mGlu2/3 receptor agonists reduce extracellular glutamate levels 
in the NAc, whereas receptor blockade increases extracellular glu-
tamate [20]. Bäckström and Hyytiä [76] tested the effects of a pre-
treatment with the mGlu2/3 receptor agonist LY379268 in attenuat-
ing alcohol-seeking behaviour and alcohol self-administration in 
rats. This experiment showed that LY379268, used at different 
doses [0, 1, 3 and 5 mg/kg intraperitoneally (i.p.)], attenuated alco-
hol self-administration and reinstatement at doses that also de-
creased spontaneous locomotor activity. Of note, similar effects 
were found for (S)-3,4-DCPG, an antagonist of the mGlu8 receptor 
(Group III) [76]. Subsequently, Rodd and colleagues [77] demon-
strated that LY404039, suppressed reinstatement of ethanol-seeking 
behaviour induced by cues but not active ethanol self-adminis-
tration. It has been suggested that the reason for the lack of effect of 
LY404039 on ethanol self-administration may be the use of a high 
ethanol-preferring P rat strain as opposed to outbred rats used in 
other studies [54]. mGluR2/3 agonists, in particular LY379268, 
modify ethanol-seeking induced both by stress and exposure to 
drug-related environmental stimuli, suggesting that mGlu2/3 recep-
tors participate in mediating the effects of contextual stimuli condi-
tioned to drugs [78]. 
 However, some of the above-mentioned effects of mGluR2/3 
agonists on drug and ethanol reinforcement or reinstatement must 
be interpreted with caution, as the effects of mGluR2/3 agonists on 
ethanol consumption may not be direct, but secondary to other ef-
fects [54]. 
 These data from animal studies suggest that Groups I and II 
mGluRs may represent promising treatment targets for stress- and 
cue-induced alcohol seeking and relapse. However, there are no 
human studies on the efficacy of either Group I mGluR NAMs or 
Group II mGluR agonists in the treatment of AD. 
CORTICOTROPIN-RELEASING FACTOR (CRF) AND 
CRF-LIKE PEPTIDES 
 Stress activates a number of biological systems in order to ap-
propriate a coordinated physiological and behavioural response. 
Two important biological stress systems, the hypothalamic-pituitary 
axis (HPA) and the locus coeruleus/norepinephrine system (LC-
NE) interact to exert their coordination of the appropriate behav-
ioural response. Individuals cope with stress differently. Aberrant 
coping mechanisms in response to stress have been linked to a wide 
range of psychiatric disorders such as depression, anxiety and drug 
and alcohol dependence [79,80]. In particular, the stress response 
has not only a key role in the development and facilitation of alco-
hol and substance abuse disorders [81], but it is also implicated in a 
behavioural component of alcohol relapse [82]. 
 Corticotropin-releasing factor (CRF) also called corticotropin-
releasing hormone (CRH), represents one of the most intensively 
studied stress-related peptides in the field of addictions. CRF is a 41 
amino acid peptide, secreted from the paraventricular nucleus 
(PVN) of the hypothalamus in response to stress. CRF is expressed 
in neuroanatomical regions associated with substance abuse and 
reward such as the central nucleus of amygdala (CeA) [83], the LC 
and the hypothalamus. Moreover, CRF appears to link two of the 
main stress response systems, namely the HPA-axis and the LC-NE 
system. This suggests a central role for CRF in coordinating and 
controlling many of the different afferents of the biological stress 
pathways and their role in substance abuse. [82-84]. Preclinical 
studies demonstrate that acute ethanol withdrawal increases CRF 
levels in the CeA [85] and in the bed nucleus of the stria terminalis 
[86] mediating stress and anxiety responses. These responses are 
reversed by non-selective CRF antagonist administration [87]. CRF 
exerts its effects on cells by binding the CRF1 and CRF2 receptors 
[88], which are members of the 7 transmembrane G-protein coupled 
receptor family. CRFR1s are found at high levels in the cerebral 
cortex, cerebellum, amygdala, hippocampus and olfactory bulb [89] 
and mediate anxiogenic properties of CRF and the coordination of 
the stress response [90]. In fact, CRFR1 null mice show decreased 
anxiety like behaviour and display an impaired stress response [91]. 
The role of the CRFR2 still remains controversial, as there is evi-
dence from animal models suggesting CRFR2 antagonists have an 
anxiolytic effect [92], however CRFR2 null mice display an anxio-
genic phenotype [93]. 
 In the genetically selected msP rats, high alcohol preference has 
cosegregated (the mutated gene and the disease are transmitted 
together to the next generation) with increased behavioural sensitiv-
ity to stress, creating a phenocopy of the postdependent phenotype. 
For example, Hansson et al. [94] identified a genetic variant in the 
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promoter region of CRFR1, which resulted in higher CRFR1 ex-
pression in several brain regions of the msP line and was associated 
with increased sensitivity to relapse into alcohol seeking induced by 
environmental stress [94]. In the same animal model, Hansson et al. 
[94] measured CRFR1 transcript in CeA, medial nucleus of 
amygdala (MeA) and NAc after two weeks of exposure to alcohol. 
In these areas, a down regulation of CRFR1 transcript was found, 
suggesting that alcohol could be voluntarily consumed by these 
animals partially for the ability of alcohol to reduce CRFR1 activity 
[95]. 
 Similarly, an upregulation of the CRFR1 transcript was present 
within the basolateral and medial amygdala in genetically non-
selected rats following a history of dependence. This upregulation 
probably contributed to their behavioural phenotype with elevated 
voluntary alcohol consumption and potentiated stress sensitivity 
during protracted abstinence. Moreover CRFR1 antagonism elimi-
nated this increased behavioural sensitivity to stress in the postde-
pendent state [96]. 
 In addition to the large body of evidence that upregulated activ-
ity of the CRF system confers susceptibility for excessive self-
administration of alcohol and relapse, there are also data linking 
genetic modulations of CRF receptors to drinking behaviour in 
humans. For example, two tagging SNPs (htSNPs) of the CRF1 
gene, rs242938 and rs1876831, were analyzed in a cohort of ado-
lescents with little previous exposure to alcohol and a cohort of AD 
adults [97]. This study linked genetic polymorphisms in CRF1 to 
risky-drinking behaviour in adolescents. In fact, there was an asso-
ciation of SNPs rs242938 and rs1876831 with binge-drinking, life-
time prevalence of alcohol intake and lifetime prevalence of drunk-
enness. In addition, the authors found an association between 
rs1876831 and high amount of drinking in AD adults. Blomeyer et 
al. [98] measured the effects of negative life events on the amount 
of drinking in the same cohort of adolescents genotyped for CRF1 
htSNPs by Treutlein et al. [97]. In this study, the C allele of htSNP 
rs1876831 was associated with drinking more alcohol per occasion 
and increased lifetime rates of heavy drinking, and this was medi-
ated by the number of negative life events in the last 3 years [98]. 
 While more research is needed to confirm this finding, the im-
pact of stress on heavy drinking could be more evident among indi-
viduals carrying a particular genotypic variant of CRF1 gene. It is 
possible that these CRF1 polymorphisms [97] may be predictive of 
response to CRF1 antagonist treatment for alcoholism, an intriguing 
pharmacological approach to treat AD. The CRF1 receptor seems to 
mediate the enhancement in ethanol self-administration during ab-
stinence period in AD models like C57BL/6J mice. In fact, the in-
crease in ethanol self-administration is less in CRFR1 knockout 
mice after dependence induction. Moreover, the CRF1 antagonist 
antalarmin reverses the enhanced self-administration in this animal 
model [99]. CRF1 antagonists selectively reduce excessive self-
administration of ethanol in alcohol dependent rats also during 
acute withdrawal, while the same antagonism has no effect on etha-
nol self-administration in nondependent animals [100]. 
 Another CRF1-receptor antagonist, (N,N-bis(2-methoxyethyl)-
3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5a]pyrimi-
din-7-amine), MPZP, blocked dependence-induced increases in 
alcohol drinking by P rats without affecting operant alcohol re-
sponding in nondependent controls [101]. 
 The newly synthesized CRF1R antagonist 3-(4-Chloro-2-
morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-
imidazo[1,2-b]pyridazine (MTIP) is a novel, orally available and 
brain-penetrant CRFR1 antagonist, which showed in vivo activity in 
preclinical models of alcoholism. Compared to other well-
characterized CRF1R antagonists, MTIP had a markedly reduced 
volume of distribution and clearance. MTIP blocked excessive al-
cohol self-administration in Wistar rats with a history of depend-
ence, as well as in a genetic model of high alcohol preference, the 
msP rat, at doses that had no effect in nondependent Wistar rats. 
Also, MTIP blocked reinstatement of stress-induced alcohol seek-
ing both in postdependent, and in genetically selected msP animals, 
again at doses that were ineffective in nondependent Wistar rats 
[102,103]. 
 Recent studies indicate that CRF is not the sole ligand of CRF 
receptors, and that the endogenous neuropeptides urocortin 1 
(Ucn1), urocortin 2 (Ucn2, also known as stresscopin related pep-
tide) and urocortin 3 (Ucn3, also known as stresscopin) also bind 
these receptors [104-106]. Moreover, these studies show that all 
three urocortins have a higher affinity than CRF at CRFR2. CRFR2 
is currently under investigation in AD. The lateral septum (LS) and 
dorsal raphe (DR) are major loci of CRFR2s [106].  
 Ucn1 binds both CRF receptors with the highest affinity. Ucn1 
in the brain is primarily expressed in the perioculomotor urocortin-
containing population of neurons (pIIIu), a brain region thought to 
be only involved in ocular function [107]. The projections from the 
non-preganglionic Edinger-Westphal (npEW) nucleus include a 
large number of brain regions. The most prominent projections 
include the LS, the DR and spinal cord [108,109]. 
 Although the regulation of Ucn1 expression is not completely 
studied or understood, results from the majority of inducible tran-
scription factors (ITFs) mapping studies indicate that the npEW is 
one of the brain areas most sensitive to ethanol, and that it is persis-
tently activated following repeated alcohol self-administration 
[110-121]. In summary, in animal models the Ucn1/CRF2 receptor 
system expression seems to be modified by prolonged ethanol ex-
posure suggesting that this system may be involved in behavioural 
changes related to AD [122]. 
 The Ucn1 system is not only sensitive, but also may be in-
volved in the genetic predisposition to high alcohol intake, as a 
number of studies evaluating the Ucn1 strains levels show higher 
Ucn 1 measures in rodent lines selectively-bred to prefer alcohol 
versus alcohol avoiding rats [123-128]. 
 Furthermore, manipulations of the Ucn1 neurocircuit modulate 
alcohol consumption and sensitivity. Mice with successful npEW 
lesions were compared to sham-operated controls and dramatic 
effects of these lesions on alcohol consumption were observed. 
Mice with npEW lesions significantly reduced their preference for 
alcohol when exposed to a choice between water and 3%, 6% or 
10% ethanol [129]. 
 The Ucn1/CRF2 neurocircuits have no apparent connections to 
the mesolimbic DA system and the amygdala. Moreover, while the 
DA system is thought to play an important role in the appetitive 
phase of reinforcement [130], there is no evidence for the involve-
ment of the Ucn1 system. Therefore, it is more likely that the npEW 
is involved in regulation of ethanol intake through effects on the 
consummatory phase of reinforcement. This regulation is most 
likely to occur through from the npEW to other brain regions. LS 
could be a target of npEW projections, which are involved in the 
regulation of this behaviour. Recent studies show that Ucn1 acts to 
depress glutamatergic transmission in the LS through CRFR2 [131-
132]. These studies lead to hypothesize a simplified neurocircuit in 
which activation of the npEW by ethanol leads to inhibition of ac-
tivity of the LS (perhaps through inhibiting the glutamatergic exci-
tation of this brain area). Since LS neurons are primarily GABAer-
gic, their inhibition by Ucn would lead to disinhibition of hypotha-
lamic target brain regions, and thereby increased to consumption of 
available fluids like ethanol. Clearly, additional studies are needed 
to fully address this hypothesis. One of the missing links in this 
scheme is the location of hypothalamic brain regions disinhibited 
through LS, and contributing to fluid intake. The hypothalamus is a 
long-proposed integrator of consummatory responses, but hypotha-
lamic subregions affected by ethanol have not been mapped in suf-
ficient detail [133]. A recent study by Ryabinin et al. [134] con-
firmed the importance of Ucn1 innervation and in particular of the 
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LS in the regulation of alcohol consumption. In a series of experi-
ments the authors injected Ucn1 or CRF bilaterally at various doses 
into the lateral septum of male C57BL/6J mice and immediately 
after the injection tested ethanol consumption. The authors used a 
limited access procedure, which takes advantage of higher levels of 
activity, fluid and alcohol consumption that are observed in mice 
during early hours into the dark portion of the circadian cycle. In-
jection of Ucn1 into the LS of C57 mice significantly attenuated 
ethanol consumption both in the expression phase of ethanol drink-
ing and during the acquisition phase of alcohol consumption [134]. 
 One potential explanation for this apparent discrepancy is that if 
Ucn1 contributes to a reward signal associated with ethanol, exoge-
nous application of Ucn1 could signal that the reward already has 
been achieved, resulting in no further effort to obtain it (by alcohol 
consumption). As an alternative explanation, since pIIIu neurons 
contain other peptides besides Ucn1 as potential regulators of the 
rewarding properties of drugs of abuse, it is possible that synergistic 
actions of these peptides are needed to increase the rewarding prop-
erties of alcohol [134]. It is important to note that Ucn3 innervates 
the same brain structures and alcohol consumption may also be 
regulated by this peptide. In particular the treatment of AD rats with 
urocortin III reduced anxiety and ethanol self-administration in the 
early stages of withdrawal [135]. 
 Although this emerging evidence strongly suggests that CRF 
receptors represent key pharmacological targets for AD, a clinical 
concern and potential limitation is that CRF1 and CRF2 agents 
might have undesirable hormonal and affective side effects, like 
impaired stress responses and abnormal anxiety-like behaviours 
[136-138].  
NEUROPEPTIDE Y (NPY) 
 Neuropeptide Y (NPY) is a 36-amino acid peptide that is ex-
pressed at high levels within the mammalian nervous system. NPY 
is one of the most abundant neuron modulators in the CNS and is 
considered an important regulating factor in emotional behaviour. 
For example, administration of exogenous NPY has anti-anxiety 
and sedative effects that rely, at least partially, on activation of Y1 
receptors in the amygdale [139-141]. The effects of NPY are medi-
ated by G-protein-coupled receptors, of which there are currently 
four subtypes identified: Y1, Y2, Y4, and Y5with Y1 and Y2 recep-
tor subtypes found at significant levels in the CNS. Antidepressant-
like actions of NPY have been reported in rats [142], and Y1- re-
ceptors seem to mediate this effect [143-144]. NPY-Y2 receptors 
also play a role in the regulation of emotion, as they are located 
presynaptically on NPY-ergic neurons and control the release of 
endogenous NPY [145]. 
 In animal models, acute and repeated stress exposure induces 
different effects in the central expression of NPY. An acute stressor 
significantly decreases NPY expression in the amygdala, an effect 
that is concurrent with the anxiogenic effects of stress. On the con-
trary, when the stressor is repeated, NPY expression is increased in 
the amygdala, correlated to a behavioural adaptation of stress [146-
147]. As a consequence, NPY expression seems to be involved in 
the behavioural adaptation to stressors [146-147].  
 Using genetically modified mice, NPY levels were inversely 
related to ethanol intake [148]. As NPY levels are lower in the CeA 
and MeA of alcohol preferring (P) rats compared to non P (NP) 
rats, NPY infusion normalizes the decreased expression of NPY in 
the CeA phosphorylation and attenuates the anxiety-like and alco-
hol drinking behaviours of P rats. Thus, a deficiency in NPY signal-
ing in the CeA may be involved in regulating both anxiety and al-
cohol drinking behaviours [149] and that NPY system modifica-
tions can influence ethanol intake [150-153]. Notably, intra-
amygdala administration of a viral vector designed to over-express 
NPY was found to have anxiolytic-like properties and to suppress 
ethanol intake in rats [154]. Moreover, intracerebroventricular 
(i.c.v.) infusion of NPY in rats has the ability to prevent stress-
induced relapse, by blocking, dose-dependently, the reinstatement 
of alcohol seeking induced by a pharmacological stress (yohimbine 
i.p.) [155]. Together, these preclinical studies suggest that in par-
ticular the NPY-Y1 receptor, may represent a novel pharmacologi-
cal target for alcoholism. Research has also focused on the possibil-
ity of the Y2 receptor to affect alcohol drinking. For example, the 
Y2 antagonist BIIE0246 suppresses alcohol intake in both naive 
[156] and postdependent animals [157].  
 In summary, targeting the NPY system, possibly through an-
tagonism at presynaptic Y2 autoreceptors, may offer an attractive 
strategy for developing novel antidepressant and anti-anxiety treat-
ments that may also affect ethanol intake. 
NOCICEPTIN 
 Nociceptin, also called Orphanin FQ (N/OFQ), is a 17-amino-
acid peptide that shows structural homology with opioid peptides, 
particularly dynorphin A [158]. N/OFQ has a high affinity with the 
opioid receptor-like 1 (ORL-1), now included in the opioid receptor 
family and renamed the NOP receptor (nociceptin/orphanin peptide 
receptor). N/OFQ and its receptor are widely distributed in the 
CNS, including areas involved with the neurobiology of addictions. 
N/OFQ has been found to act in the brain as a functional antiopioid 
peptide by blocking opioid-induced supraspinal analgesia [159-
160], morphine-induced conditioned place preference [161], and 
morphine induced increases in extracellular DA levels in the NAc 
[162]. Moreover, N/OFQ inhibits stress-induced ethanol seeking 
and exerts general anti-stress-like effects by acting as a functional 
antagonist of extrahypothalamic CRF transmission [163]. 
 Genetic variants of the N/OFQ and NOP genes may be linked 
to vulnerability for alcoholism. One study revealed a link between 
alcoholism and two SNPs in the N/OFQgene [164]. Moreover, the 
SNP rs6010718 of the gene encoding the NOP receptor was associ-
ated with the diagnosis of AD in a Scandinavian sample [165]. 
 Several studies demonstrate that N/OFQ regulates ethanol pref-
erence, ethanol reward, and ethanol-seeking behaviour. For exam-
ple, activation of NOP receptors by N/OFQ inhibits home cage 
ethanol drinking and operant ethanol self-administration. N/OFQ 
also reduces both ethanol-induced conditioned place preference and 
conditioned reinstatement of alcohol seeking [166-168]. Moreover, 
N/OFQ inhibits stress-induced ethanol seeking and exerts general 
antistress effects by acting as a functional antagonist of extrahypo-
thalamic CRF transmission [169-170]. Studies using alcohol prefer-
ring msP rats demonstrated that subchronic administration of 
N/OFQ or N/OFQ analogs significantly reduce ethanol self-
administration [171-172]. By contrast, in nonselected Wistar rats 
tested under the same experimental conditions, N/OFQ did not alter 
ethanol consumption [173]. Studies with in situ hybridization re-
vealed higher expression levels of N/OFQ and NOP receptor 
mRNA in numerous brain areas of msP compared to Wistar rats 
[173]. 
 Recent data show that the opioid agonist/partial agonist bu-
prenorphine reduces alcohol intake in msP rats via activation of 
NOP receptors [174]. This last observation not only strengthens the 
link between N/OFQ and excessive alcohol consumption, but also 
suggests potential clinical applications. This is consistent with the 
observation that buprenorphine reduces not only opiate use but also 
alcohol intake in heroin dependent subjects [175]. In summary, 
these data provide the rationale for the development of N/OFQ 
receptor agonists as new pharmacotherapies for the treatment of 
AD. 
SUBSTANCE P AND NEUROKININ 1 (NK1) RECEPTOR  
 Substance P (SP) is an 11 amino acid peptide [176] involved in 
C-fiber sensory transmission wherein blockade of the transmission 
of SP produces analgesic and anti-inflammatory effects [177]. Sub-
stance P and its receptor Neurokinin 1 receptor (NK1R) are highly 
expressed in brain regions involved in drug reward and affective 
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behaviours (for review see [178]). NK1R agonists have anxiogenic-
like effects and cause conditioned place aversion. Conversely, 
NK1R antagonists produce anxiolytic-like and antidepressant-like 
effects [178] as human studies demonstrate that antagonism of SP 
or of NK1R to be effective for depression or anxiety [179-181]. 
Despite this early evidence of efficacy in treating affective disor-
ders by NK1R antagonists, no further studies were published.  
 More recently, there has been an interest in the role of NK1R as 
a potential pharmacological target for alcoholism. This interest was 
based on the preclinical evidence that genetic deletion of NK1R 
suppresses alcohol intake [182]. Conversely, inactivation of NK1R 
but not NK1R antagonism critically seems to modulate alcohol 
reward and escalation of alcohol intake following multiple depriva-
tions, two important characteristics of addiction.  
 In humans, a recent study tested the high-affinity selective 
NK1R antagonist LY686017, a compound characterized by oral 
availability and brain penetrance [183]. LY686017 was adminis-
tered daily to 50 recently detoxified patients with a diagnosis of AD 
and with high trait anxiety [Spielberg Trait Anxiety Inventory Test 
(STAI) > 39]. LY686017 was administered at the dose of 50 mg 
daily, which yields a > 90% blockade of central NK1R. LY686017 
was significantly more effective than placebo in suppressing spon-
taneous alcohol craving, improving overall well-being, blunting 
cravings induced by a laboratory challenge procedure, and attenuat-
ing cortisol response. Finally, an examination of allelic variations in 
the NK1R gene in 271 alcoholic subjects and in 337 healthy con-
trols found that the development of AD in Caucasian individuals is 
significantly associated with some polymorphisms of the NK1R 
gene [184]. 
 In summary, preclinical and clinical evidence suggest that 
NK1R antagonism might be of therapeutic value in alcoholism. 
Future studies will have to identify the best population responding 
to NK1 R antagonism. In this regard, considering that Substance P 
acts at NK1Rs to mediate both behavioural stress responses and 
drug reward mechanisms, the NK1R antagonist aprepitant is cur-
rently under investigation for the treatment of alcoholics with Post-
traumatic Stress Disorder (PTSD) co-morbidity (NCT00896038). 
NEUROKININ B AND TACHYKININ RECEPTORS 
 Similar to NK1 receptors, tachykinin receptors 3 (NK3Rs), the 
receptors for the tachykinin 3 peptide (neurokinin B) are involved 
in drug reward mechanisms. In particular, it was hypothesized that 
NK3R agonists reduce ethanol consumption by replacing the re-
warding properties of alcohol, thus making alcohol consumption 
redundant [185, 186]. A preclinical study in Sardinian preferring 
and non-preferring rats reported that administration of the selective 
NK3R agonist senktide inhibits alcohol intake, without affecting 
overall water or food intake [187, 188]. The brain regions that were 
highly sensitive to the inhibitory effect of the tachykinin NK3R 
agonists were the lateral hypothalamus and the nucleus basalis 
magnocellularis [189].  
 Because of mouse, rat and human species differences in the 
NK3R, no clinical trials have been carried out to evaluate the effi-
cacy of NK3R agonists in reducing ethanol consumption in humans 
[190]. However, a recent study within the Collaborative Study on 
the Genetics of Alcoholism (COGA) found evidence of an associa-
tion between a variation in TACR3 gene and susceptibility for AD 
[190]. TACR3 belongs to a family of genes that encode proteins 
that function as receptors for tachykinins (including NK3R for neu-
rokinin B). Interestingly, a secondary analysis showed that variation 
in TACR3 was associated with more severe alcoholism [190].  
 Unlike NK1 and NK3 receptors, tachykinin NK2 receptors are 
not highly abundant in the CNS, although NK2 receptor mRNA and 
NK2 receptor binding sites have been identified in the human brain 
[191]. The selective NK2R antagonist saredutant (SR48968) s has 
anxiolytic- and antidepressant-like activities [192]. However, 
NK2Rs seem to be less involved in reward processes. For example, 
a study by Ciccocioppo and colleagues [193] showed that the NK2 
selective agonist GR 64349, unlike the NK3 selective agonists, did 
not inhibit alcohol intake in Sardinian alcohol-preferring rats. How-
ever, no further studies have been conducted to confirm these find-
ings. 
NEUROPEPTIDE S 
 The 20 amino-acid peptide Neuropeptide S (NPS) and its recep-
tor NPSR were first identified in 2004, as a novel transmitter sys-
tem, mainly expressed in the brain [194]. NPS is co-expressed with 
excitatory transmitters such as glutamate, acetylcholine or CRF. 
While the projection areas of these NPS-producing neurons are 
currently unknown, however, outside of the CNS, the NPS precur-
sor is expressed mainly in endocrine tissues [195]. The NPSR is a 
typical member of the G-protein-coupled receptor superfamily and 
is expressed in brain areas involved in olfactory processing, in brain 
areas critical for fear processing (e.g. amygdala and paraventricular 
nuclei of the hypothalamus), as well as in brain regions involved in 
sleep-wake modulation (e.g. thalamic intralaminar nuclei, preoptic 
nucleus or tuberomammillary nucleus). Thus, the NPS system me-
diates specific effects on synaptic transmission to and within the 
amygdala, which are important for processing of acute fear as well 
as extinction of fear memories [196]. Ruggeri et al. [197] investi-
gated the variations of NPSR mRNA expression in rats exposed to 
6 days of intermittent ethanol intoxication and demonstrated an 
increased NPSR mRNA expression in different brain areas of post-
dependent rats. Central activation of NPS receptors facilitates re-
lapse to alcohol seeking. Thus, considering that postdependent rats 
are more inclined to relapse, one could speculate that this over ex-
pression may also be functionally relevant in alcohol drinking 
[198]. Another recent experiment sought to determine whether the 
NPS system might play a role in the regulation of alcohol-related 
behaviours [199]. This study showed that i.c.v. NPS does not mod-
ify ongoing ethanol self-administration in rats, indicating that moti-
vational circuitry of ethanol reinforcement is not directly affected 
by activation of NPSR. On the other hand, recent data by Badia-
Elder et al. [200] showed that i.c.v. NPS injection signifi-cantly 
reduces ethanol drinking in genetically selected alcohol preferring P 
rats. Experimental design differences may explain the discrepant 
results of the two studies. Badia-Elder et al. [200] tested the effect 
of NPS on home cage voluntary ethanol drinking, whereas Cannella 
et al. [199] studied peptide effects under operant conditions. Oper-
ant self-administration is thought to more directly gauge motivation 
to obtain the reinforcer, whereas home cage drinking can also be 
controlled by taste, calories and other factors not directly related to 
pharmacological reinforcement. Furthermore, the P rats show ele-
vated anxiogenic-like behaviour and it has been hypothesized that 
their excessive ethanol drinking is in part driven by reduction of 
anxiety symptoms. Notably, NPS has anxiolytic-like effects in ani-
mal models of anxiety [201, 202]. 
 Moreover, Cannella and collegues [199] showed a three-fold 
increase of relapse in rats subjected to repeated reinstatement test-
ing. As the lateral hypothalamus (LaH) is traditionally implicated in 
reward and motivation and is one of the brain areas with the highest 
NPSR transcript expression levels, Canella et al. [199] demon-
strated that intra-LaH administration dramatically reinstated extin-
guished ethanol responding suggesting that the LaH is an important 
brain site of action for NPS effects on alcohol relapse.  
GALANIN 
 Galanin is a feeding-stimulatory peptide with neuroprotective 
effects. In fact, increased galanin concentrations seem to have neu-
roprotective effects and promote neurogenesis [203]. The three 
galanin receptors (GalR1, GalR2, GalR3), are involved, centrally, 
in the control of feeding, alcohol intake, seizure threshold, cogni-
tive performance and mood, and peripherally, in the control of pain 
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threshold [203]. Both human genetic and behavioural animal stud-
ies have suggested that galanin may be involved in addictive behav-
iours, such as repeated alcohol intake. Earlier studies showed that 
hypothalamic injection of galanin increases the release of DA in the 
NAc, just as systemic alcohol does [203]. In humans, a genetic 
study found a significant association between the single nucleotide 
polymorphism (SNP) rs3091367 of the GalR3 and alcoholism, sug-
gesting that galanin’s influence on alcoholism vulnerability may be 
mediated mainly through GalR3 [204]. This finding suggests that 
the development of galanin receptor ligands, in particular GalR3 
antagonists, might be useful in the treatment of AD. 
GHRELIN 
 Ghrelin is a 28-amino acid gut peptide with an n-octanoylation 
modification at Ser 3 [205]. Ghrelin acts as the endogenous ligand 
for the growth hormone secretagogue receptor (GHS-R), a G-
protein coupled receptor that induces growth hormone (GH) release 
from the pituitary [205]. Ghrelin’s discovery was related to its abil-
ity to stimulate GH release. Subsequently, it has clearly demon-
strated that ghrelin affects food-seeking behaviour, stimulating 
appetite and food intake. Ghrelin stimulates appetite by acting on 
the hypothalamic arcuate nucleus (ARC), a region that controls the 
intake of food and other substances, including alcohol. Opioidergic 
neurons, which play a role in the reinforcing effects of alcohol, also 
are located in the ARC [206]. In addition to the ARC, GHS-Rs are 
also highly expressed in the caudal brain stem, the VTA, hippo-
campus, substantia nigra, and dorsal and medial raphe nuclei [207, 
208]. The expression of the GHS-R in the mesolimbic DA pathway 
suggests that ghrelin could also modulate the hedonic properties of 
food and the so-called reward system [209,210]. This hypothesis 
has been tested in animals. Intracerebral ventricular (i.c.v.) ghrelin 
administration into the third ventricle increases extracellular con-
centrations of accumbal DA in NMRI mice [209], also showing that 
ghrelin activates the cholinergic-dopaminergic reward link and that 
ventral tegmental nAChRs have a central role for the DA-enhancing 
properties of ghrelin. A second set of experiments extended the 
previous results, injecting ghrelin directly into the VTA [211]. 
These findings were replicated when ghrelin was injected peripher-
ally [212]. A more recent set of experiments used an elegant ap-
proach of genetic (GHS-R1A knockout mice) and pharmacological 
(two GHS-R1A antagonists: BIM28163, delivered i.c.v; and 
JMV2959, i.p.) models of suppressed ghrelin signaling [213]. These 
experiments demonstrated that: i) alcohol-induced brain reward 
parameters, such as enhanced extracellular accumbal DA overflow, 
locomotor stimulation and conditioned place preference (CPP) were 
consistently abolished or attenuated by two GHS-R1A antagonists 
in wild-type mice and were abolished in GHS-R1A knockout mice; 
ii) i.c.v. administration of ghrelin to mice significantly increased 
alcohol consumption compared to vehicle treatment in a 2-bottle 
(alcohol/water) free choice limited access paradigm. Bilateral ad-
ministration of ghrelin into either the VTA or the LDTg also in-
creased alcohol consumption in comparison to vehicle. The per-
centage increase in alcohol consumption was significantly greater 
following administration to the VTA or the laterodorsal tegmental 
nucleus (LDTg) compared to the i.c.v. route. Food intake (normal 
chow) was increased by i.c.v. ghrelin administration in comparison 
to vehicle but was not affected by bilateral ghrelin administration 
into either the VTA or the LDTg. Alcohol intake in the 2-bottle 
(alcohol/water) free choice limited access paradigm was suppressed 
in mice by both the GHS-R1A antagonists (delivered either i.c.v. or 
i.p.). The effects of i.c.v. ghrelin on alcohol intake were absent in 
GHS-R1A knockout mice.  
 Human studies also shed light on the acute effects of alcohol on 
ghrelin as well as on the possible role of ghrelin in alcohol-seeking 
behaviour. In alcoholics, alcohol is able to acutely inhibit ghrelin 
secretion and plasma ghrelin levels correlate with psychometric 
determinations of the alcohol seeking behaviour, such as alcohol 
craving (for review, see [214]). 
Together, these findings suggest that ghrelin system plays a role in 
AD, thus representing a new possible pharmacological target.  
GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR 
(GDNF) 
 The glial cell line-derived neurotrophic factor (GDNF) is a 
distant member of the transforming growth factor ? superfamily 
that was originally isolated from the rat B49 glial cell line. High 
levels of the growth factor are found in the striatum (dorsal striatum 
and NAc), thalamus, cortex and hippocampus. The major source of 
GDNF in the midbrain is the striatum where GDNF is retrogradely 
transported by dopaminergic neurons of the substantia nigra pars 
compacta (SNc) and the VTA [215]. GDNF plays an essential role 
in the development and survival of motor neurons, in the synapto-
genesis and is an essential factor for the maintenance and survival 
of adult DA neurons. Moreover GDNF seems to regulate neuronal 
excitability and transmitter release [216]. 
 Dopaminergic neurons within the VTA are a critical component 
of the neural circuitry implicated in addictive behaviours [217]. 
GFR?1 and transfection receptor (Ret) are highly expressed in VTA 
dopaminergic neurons and increasing evidences suggest that GDNF 
plays a regulatory role in the actions of drugs of abuse, including 
ethanol.  
 Recent studies showed that GDNF inhibits ethanol-drinking 
behaviours. A single administration of GDNF into the VTA of rats 
results in a rapid reduction of operant self-administration of ethanol 
[218,219]. Moreover the administration of GDNF into the VTA 
reduces consumption of moderate levels of ethanol in a paradigm 
that resembles social drinking [218,219]. On the other hand, in 
models of excessive and “binge-like” drinking of ethanol (i.e. using 
a 20% ethanol solution), GDNF infusion in the VTA also reduces 
ethanol consumption by lever presses [219,220]. 
 Considering an animal model of relapse, Carnicella and col-
legues [219] found that activation of GDNF pathway in the VTA 
reduces self-administration of ethanol. Together, these results sug-
gest that GDNF is a potent, rapid inhibitor of excessive consump-
tion and relapse to ethanol. 
 The main signaling pathways activated via GDNF-mediated-
Ret activation are the MAPK, PI3K and PLC?. In the VTA, a spe-
cific inhibition of MAPK blocked GDNF-mediated reduction in 
ethanol self-administration [219]. Thus, the MAPK seems the spe-
cific signalling pathaway by which GDNF mediates a reduction in 
ethanol-drinking behaviours. GDNF rapidly inhibits the activity of 
A-type K+ channel currents in primary midbrain neurons via a 
mechanism that requires the activation of the MAPK pathway 
[221]. Therefore, it is possible that GDNF, via the inhibition of an 
A-type K+ channel, alters the excitability of the neurons in the 
VTA, leading to the decrease in ethanol self-administration. 
 On the other hand, the long-lasting actions of GDNF may be 
explained by GDNF-induced transcriptional changes, that could 
persist beyond the activation and termination of GDNF signaling. 
[222]. Moreover GDNF upregulates its own expression, leading to a 
prolonged activation of the GDNF signaling pathway [223]. In 
addition, several studies suggest a role for GDNF in the regulation 
of tyrosine hydroxylase (TH), the rate-limiting enzyme in the bio-
synthesis of DA in the midbrain [220]. Upregulation of TH levels 
has been reported as one of the hallmarks of biochemical adapta-
tions to in vivo chronic exposure to drugs of abuse, including etha-
nol [224]. 
 All these data suggest that GDNF plays an important role in 
controlling ethanol drinking behaviours and suggest that upregula-
tion of the GDNF pathway may be an approach to treat AD. How-
ever, it is unlikely that GDNF itself could be used as a therapeutic 
agent considering that it cannot cross the blood-brain barrier [225]. 
Some recent studies suggest the possible use of small molecules 
that increase the production of GDNF or activate its receptors. 
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There are several small molecules that have been reported to in-
crease the expression of GDNF or activate the GDNF signalling 
pathway. Ibogaine is a natural alkaloid reported to reverse the ad-
verse actions of multiple drugs of abuse including alcohol [226]. 
Systemic administration of ibogaine in rats reduces ethanol self-
administration and relapse and increases GDNF expression, result-
ing in the activation of the GDNF pathway [227]. Importantly, the 
actions of ibogaine in reducing ethanol intake were localized into 
the VTA, and infusion of anti-GDNF neutralizing antibodies into 
the VTA attenuated the ibogaine-mediated decrease in ethanol self-
administration [227]. Despite its attractive properties, ibogaine can 
induce severe side-effects such as hallucinations, whole-body trem-
ors and ataxia that may be related to neurotoxicity in the cerebellum 
and dysregulation of the cardiovascular system [226]. 
 A potential strategy to overcome these undesirable actions of 
ibogaine is the use of derivatives like noribogaine and 18-methoxy-
coronaridine (18-MC). 18-MC was found to reduce ethanol intake 
in rodents, without affecting water consumption [228]. Importantly, 
these ibogaine-derived metabolites have no tremorigenic effects or 
evidence of cerebellar toxicity in animals [228]. 
 Cabergoline, a D2-like receptor agonist, increases GDNF ex-
pression and secretion in cultured astrocytes [229]. Systemic ad-
ministration of cabergoline significantly reduces operant ethanol 
self-administration in rats [230]. Moreover, systemic administration 
of cabergoline reduced both the reacquisition of operant responding 
for ethanol after a period of extinction and cue-induces ethanol-
seeking after abstinence (which represents two different models of 
relapse) [230]. These results suggest that cabergoline decreases 
ethanol-drinking and ethanol-seeking behaviours, and that these 
effects are mediated by the upregulation of the GDNF pathway in 
the mesolimbic system. Thus, cabergoline deserves future investi-
gations as a new alcohol pharmacotherapy [220]. 
ACETALDEHYDE (ACD) 
 Three main enzymatic pathways, namely alcohol dehydro-
genase (ADH), cytochrome P4502E1 (CYP2E1) and catalase, me-
tabolize ethanol to acetaldehyde (ACD). Acetaldehyde, the first 
product of ethanol metabolism, plays a key role in the toxic effects 
of ethanol and has also been identified as a potential psychoactive 
drug able to induce some behavioural effects. It has been proposed 
that ACD is a key mediator of ethanol’s neuropharmacological and 
behavioural effects. Although controversial and not fully accepted, 
according to this hypothesis, ethanol would be a mere pro-drug 
whose effects are fully mediated by its first metabolite ACD [232]. 
Thus, a number of behavioural studies focused on ACD reinforcing 
properties and demonstrated that ACD self-administration is much 
easier to establish than ethanol self-administration [232, 233]. Thus, 
it was proposed that ACD is a stronger reinforcer than its parent 
drug ethanol. Recently, ACD was similarly shown to be a 1000-fold 
more potent reinforcer than ethanol when tested for self-
administration into the VTA, a brain region strongly involved in 
ethanol reinforcing effects [234]. The reinforcing properties of 
ACD were also confirmed in place conditioning studies [235,236]. 
Notably, this place preference was stronger in rats genetically se-
lected for their high ethanol preference [237]. Moreover ACD self-
administration increased subsequent voluntary alcohol consumption 
in a free choice procedure [238,239]. 
 These data support the hypothesis that ACD participates in 
ethanol’s psychoactive effect through its own rewarding properties. 
Acetaldehyde seems to have a key role as a mediator of the 
mesolimbic DA-stimulating effects following ethanol ingestion. In 
fact, in animal models both ethanol and ACD administration in-
crease NAc DA release [240].  
 Consistent with in vivo reports, in vitro studies confirmed a 
crucial role of ACD in alcohol induced activation of midbrain DA 
cells. When ACD formation is prevented, ethanol ceases to enhance 
the spike frequency of DA neurons, suggesting that ACD mediates 
ethanol-induced effects on DA neuronal spontaneous activity. Fur-
ther evidence is provided by the observation that ACD dose depen-
dently produces a fast increase in DA neuronal firing activity [240-
242]. Cysteine, (2R)-2-amino-3-sulfanyl-propanoic acid, is not an 
essential amino acid with a thiol side chain. Cysteine is efficacious 
to bind ACD derived from alcohol drinking to prevent the possible 
role of ACD in digestive tract cancer [243-245], alcoholic cardio-
myopathy [246], as well as to prevent ACD chronic toxicity [247] 
and oxidative damage [246]. In Wistar rats, pretreated i.p. with 
saline or L-cysteine, followed by intragastric administration of sa-
line, ethanol , or ACD, L-cysteine dose-dependently prevented both 
ethanol and ACD-induced conditioned place preference [248]. In 
the same animal model, pretreatment with L-cysteine reduced both 
acquisition and maintenance of oral ethanol self-administration 
behaviour [249]. In addition, pretreatment with L-cysteine reduced 
reinstatement of ethanol-drinking behaviour after an oral ethanol 
extinction [249]. These experiments show that L-cysteine reduces 
all phases of oral ethanol self-administration. The efficacy of L-
cysteine on relapse to alcohol drinking represents an interesting 
pharmacological approach and could lead to new alcohol pharma-
cotherapies [249]. 
KUDZU 
 Several genetic and clinical observations indicate that a selec-
tive deficiency of aldehyde dehydrogenase 2 (ALDH-2) is often 
associated with reduced drinking and risk for alcoholism [250]. 
Subjects with ALDH-2 deficiency, such as 15 to 40% of Southeast 
Asians, have an inactivation of ALDH-2 due to an E487K mutation 
[251]. These individuals, after taking alcohol, experience unpleas-
ant symptoms due to the accumulation of ACD [250]. Acetaldehyde 
is a product of hepatic alcohol dehydrogenase (ADH) and is me-
tabolized to acetate by cytoplasmic ALDH-1 and mitochondrial 
ALDH-2. 
 It was suggested that administration of drugs that inhibit ALDH 
activity and consequently, induce elevations in ACD, discourage 
alcoholics to continue drinking. It should be noted that although 
low levels of brain ACD may be reinforcing in the VTA, high sys-
temic concentrations of ACD are aversive, producing nausea, dia-
phoresis and tachycardia. The most studied drug with this mecha-
nism of action is the FDA-approved medication disulfiram (see 
[10]), a nonspecific toxic and irreversible inhibitor of both mito-
chondrial ALDH-2 and cytoplasmic ALDH-1 [252]. However, 
disulfiram may have non-specific toxicity caused by chelating met-
als and reacting with sulfhydryl groups to inactivate diverse pro-
teins and other enzymes, in addition to ALDH-1 and ALDH-2. 
Thus, research has focused on identifying more selective inhibitors 
of mitochondrial ALDH-2. Kudzu and kudzu extracts have been 
identified as such compounds. Kudzu is a perennial leguminous 
vine of the genus Pueraria lobata native to eastern Asia [253]. 
Puerarin, daidzin, and daidzein are three of the major isoflavonoid 
compounds isolated from the extract of Pueraria lobata [253]. The 
anticraving and “antidrunkeness” effects of extracts of Pueraria 
lobata have been known to traditional Chinese Medicine for centu-
ries, but its true efficacy and the mechanism(s) of action of its ac-
tive principle(s) were unproven. 
 Daidzin was first shown to suppress ethanol intake in ethanol 
preferring Syrian golden hamsters [254]. Subsequently, it was 
found that all three isoflavonoid compounds were effective in sup-
pressing voluntary alcohol consumption in alcohol-preferring (P) 
rats. In particular, daidzein, daidzin, and puerarin, orally adminis-
tered to P rats at a dose of 100 mg/kg/day, decrease ethanol intake 
by 75%, 50%, and 40%, respectively [255]. The efficacy of Puer-
aria lobata extracts in reducing voluntary alcohol consumption has 
been confirmed in all ethanol-drinking animals tested to date [256-
260]. The most recent preclinical study tested the efficacy of a 
highly selective reversible ALDH-2 inhibitor, CVT-10216, in mod-
els of moderate and high alcohol drinking rats [261]. Results of this 
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study showed that treatment with CVT-10216 reduces heavy drink-
ing in rodents, suppresses alcohol self-administration, deprivation-
induced drinking and cue-induced reinstatement of alcohol-seeking, 
an animal model of relapse. The authors suggested that CVT-10216 
may prevent alcohol-induced increase in NAc DA.  
 A study by Xie and colleagues [262] showed that i.p. admini-
stration of daidzin reduces intoxication induced by anaesthetic 
doses of alcohol in rats. Notably, the effects of daidzin in shorten-
ing alcohol-induced sleep time, a reliable measure of alcohol in-
toxication, was found after intragastric, but not i.p. infusion of al-
cohol, suggesting that the effects of daidzin are also due to a slow-
down of gastric emptying, which would expose alcohol for a longer 
time to first-pass metabolism [263]. Some effects in reducing alco-
hol withdrawal symptoms were also observed for daidzein and pu-
erarin [259,260,264]. In particular, Overstreet and colleagues 
showed that the extract of kudzu NPI-031G (puerarin) was effective 
in counteracting anxiogenic effects associated with alcohol with-
drawal in rats exposed chronically to alcohol, suggesting an under-
lying mechanism of antagonism at the benzodiazepine receptors 
[264].  
 In humans, a randomized double-blind controlled trial evaluated 
the efficacy of kudzu root extracts in influencing drinking habits of 
veterans who entered a substance abuse treatment program [265]. 
Alcohol dependent patients were randomly assigned to receive 
kudzu root extracts 1.2 g twice daily (21 patients) or a matching 
placebo (17 patients). In this small sample, kudzu root was no better 
than placebo in reducing alcohol craving, or in promoting absti-
nence [265]. A subsequent clinical trial was conducted to evaluate 
the efficacy of a kudzu extract in heavy drinkers treated with either 
a kudzu extract or placebo for 7 days [266]. Participants had then 
the opportunity to drink their preferred brand of beer while in a 
laboratory setting. Results of this study showed a significant reduc-
tion in the number of beers consumed in one week of treatment, as 
well as an increase in the number of sips, an increase in the time to 
consume each beer and a decrease in the volume of each sip. There 
were no changes in the urge to drink alcohol, suggesting that kudzu 
probably does not act blocking alcohol’s effects but instead pro-
longing or enhancing the acute effects of the first drink [266].  
NICOTINIC AND MUSCARINIC ACETYLCHOLINE RE-
CEPTORS (nAchRs AND mAchRs) 
 The central cholinergic system has been implicated in the de-
velopment of alcohol and drug addictions. The receptors of the 
cholinergic system are divided into muscarinic acetylcholine recep-
tors (mAchRs) and nicotinic acetylcholine receptors (nAchRs). The 
potential role of nAchRs in the treatment of alcohol and drug addic-
tions has been more extensively studied than that of mAchRs [267]. 
 Mesocorticolimbic DA neurons are known to contain central 
nAchRs that modulate the accumbal release of DA [268]. Alcohol-
induced stimulation of the mesolimbic DA system may involve 
central nAchRs, suggesting their possible involvement in the initia-
tion phase of alcohol consumption [269]. Other experiments also 
demonstrated an involvement of these receptors in the mechanisms 
of maintenance of alcohol consumption and relapse to alcohol use 
[269]. Blomqvist and Ericson have extensively studied the in-
volvement of nAchRs in the mechanisms of alcoholism and found 
that ethanol activates the mesocorticolimbic DA system via both 
direct and indirect stimulation of central nAchRs NAc [270,271]. 
Moreover, mecamylamine, a blood brain barrier penetrating nAchR 
antagonist, completely antagonizes both of these effects [272]. On 
the basis of these observations, the effects of two nAchR antago-
nists, mecamylamine and hexamethonium, as well as the effects of 
subchronic nicotine treatment on voluntary ethanol consumption 
were studied in ethanol low-, medium- or high-preferring Wistar 
rats [270]. Mecamylamine but not hexamethonium reduced ethanol 
intake in high-preferring rats, while subchronic nicotine treatment 
increased ethanol consumption in rats with a medium preference for 
alcohol. Neither mecamylamine nor hexamethonium reduced etha-
nol preference. On the basis of these results, the authors suggested 
that antagonists at nAchRs could be useful compounds in the treat-
ment of alcoholic subjects [270]. A subsequent study by the same 
research group provided further evidence on the possible role of 
mecamylamine in the treatment of alcoholism [273] as ethanol in-
take and preference in Wistar rats were markedly reduced and DA 
levels were unaltered with respect to pre-drug baseline levels [273]. 
In a more recent study, Farook and colleagues [274] using alcohol-
preferring C57BL/6J mice reported that there was a reduced con-
sumption of alcohol in daily and intermittent mecamylamine-treated 
(intermittent) mice than in control mice.  
 Twelve different nAchR subunits (?2-?10 and ?2-?4) have been 
identified and these subunits can constitute a multitude of pen-
tameric nAchRs with different molecular configurations. These 
nAchRs are expressed in varying patterns and densities throughout 
the brain, e.g. the mRNAs for the nAchR subunits ?3-?7 and ?2-?3 
have been found highly expressed within the VTA [275]. Moreover, 
variations in the nAchR subunit composition may influence the 
sensitivity to ethanol. In order to examine the role of different 
nAchR subunits in operant ethanol self-administration and in etha-
nol drinking relapse following a 10-day period of ethanol depriva-
tion, Kuzmin and colleagues [275] compared the nicotinic subunit-
specific antagonist ?-conotoxin MII (?CtxMII, ?3 ?2, ?3, ?6) with 
systemic mecamylamine, dihydro- ?-erythroidine (DH?E, ?4 ?2) 
and methyllycaconitine (MLA, ?7). ?CtxMII was administered 
directly into VTA, whereas mecamylamine, DH?E and MLA were 
administered systematically. Results of the study showed that 
?CtxMII reduced operant ethanol self-administration and blocked 
the deprivation-induced relapse-like ethanol consumption; mecamy-
lamine reduced operant ethanol self-administration and inhibited 
the deprivation-induced increase in alcohol consumption; DH?E 
inhibited ethanol intake only at a higher dose; MLA failed to block 
self-administration of ethanol and relapse-like drinking after depri-
vation. These results suggested that modulation of central effects of 
ethanol are mediated mainly by ?3?2 and/or ?3 subunits of 
nAchRs. Therefore, ligands for these subunits might be of greater 
interest for alcohol pharmacotherapies [275].  
 Lobeline is a naturally occurring alkaloid obtained from the 
plant Lobelia inflate, that binds to nAchRs with high affinity, dis-
playing both agonist and antagonist activity. In a recent study, the 
effects of repeated administration (continuous or recurring for 5 
days) of the partial nicotinic agonist lobeline on alcohol consump-
tion and alcohol preference were investigated in a high alcohol 
preferring strain of mice [276]. Lobeline attenuated alcohol 
consumption and preference during both the repeated-recurring and 
continuous administration phases, probably by activating both high 
(?4?2) and low affinity (?7) central nAchRs [276]. The effects of 
lobeline and of the nAchR partial agonist cytosine on ethanol drink-
ing were then investigated by Bell and colleagues [276]. At high 
doses both nAchR ligands independently suppressed ethanol intake. 
Specifically, cytosine suppressed ethanol intake, by attenuating 
?4?2 nAchR function and lobeline suppressed ethanol intake, by 
acting as a nonselective competitive antagonist at ?4?2 and ?3?2 
nAchRs. Practically, both cytosine and lobeline act as functional 
antagonists at nAchRs, which in turn lead to reduce alcohol induced 
DA release in the NAc and consequently, to attenuate the reinforc-
ing properties of ethanol. 
 Varenicline, a cytosine derivate, is a partial agonist at the ?4?2 
nAchRs and has been approved for marketing in the U.S. and in 
more than 30 countries worldwide as an aid for smoking cessation 
[277]. Varenicline, at higher concentrations, can interact with other 
nAchRs subtypes, in addiction to ?4?2, including the ?7 ho-
momeric receptor subtype. A role of ?7 nAChRs in modulation of 
ethanol response has been hypothesized, although a recent study 
using mice with a constitutive knockout of either the ?7 or ?2 
subunit found that neither subunit is absolutely required for the 
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effect of varenicline on ethanol intake [278]. Steensland and col-
leagues [279] investigated the role of varenicline in the modulation 
of alcohol consumption and alcohol seeking using three different 
animal models of drinking. Acute administration of varenicline, in 
doses reported to reduce nicotine reward, selectively reduced etha-
nol but not sucrose seeking and decreased voluntary ethanol con-
sumption in animals chronically exposed to ethanol for two months 
before varenicline treatment. Moreover, chronic varenicline ad-
ministration reduced ethanol consumption, which did not result in a 
rebound increase in ethanol intake when varenicline was discontin-
ued. Furthermore, varenicline appears to ameliorate ethanol-indu-
ced cognitive deficits, in particular deficits in acquisition of contex-
tual and cued associative learning [280].  
 Few studies investigating the efficacy of nAChRs ligands in the 
treatment of alcoholism have been conducted in humans. The first 
clinical study by Blomqvist and co-workers [281] investigated the 
effects of mecamylamine on subjective responses of healthy sub-
jects to a moderate dose of alcohol. Results of the study showed 
that mecamylamine, as compared to placebo, reduced the stimulant 
and pleasurable effects of an acute administration of alcohol during 
the ascending limb of the blood alcohol curve, probably by modify-
ing both the pharmacokinetic profile of alcohol and the rewarding 
effects. Chi and de Wit [282] replicated and extended this study 
using a double-blind design. As compared to placebo, mecamy-
lamine reduced subjective euphoria after alcohol intake and desire 
to consume more alcohol. However, a more recent study with me-
camylamine did not confirm these observations [283]. To date only 
one human study using varenicline for alcoholism has been pub-
lished [284]. This study was a double-blind, placebo-controlled trial 
in which the effect of varenicline (2 mg/day vs. placebo) on alcohol 
self-administration was investigated in 20 non alcohol-dependent 
heavy drinkers who were also daily smokers. After seven days of 
medication pre-treatment, subjects were first administered a prim-
ing dose of alcohol (3g/kg) and subjective and physiologic re-
sponses were assessed. The participants were exposed to a 2-hour 
drinking period during which they were permitted to drink up to 
eight alcoholic drinks or to receive monetary reinforcement for each 
drink not consumed. Results showed that varenicline significantly 
reduced the number of drinks consumed compared to placebo and 
increased the likelihood of abstaining from any drinking during the 
self-administration period. Furthermore, following the priming 
drink, varenicline attenuated alcohol craving and reduced subjective 
reinforcing alcohol effects, without significant side effects.  
 These promising results have aroused interest in respect of va-
renicline as a new medication target for alcohol use disorders. In 
fact, there are several ongoing clinical and human laboratory trials 
designed to investigate both the effects of varenicline on heavy 
drinking and the effectiveness in the treatment of AD (e.g. 
NCT00846859, NCT01071187, NCT00695500). 
 Muscarinic acetylcholine receptors (mAchRs) are predomi-
nantly presynaptic autoreceptors, being responsible for acetylcho-
line-mediated inhibition of adenyl cyclase activity. mAchRs pri-
marily provide negative feedback on acetylcholine release from 
cholinergic terminals [285] and are involved in many brain func-
tion, including attention, learning, memory and cognition [286]. 
Several studies showed an association between the muscarinic ace-
tylcholine M2 receptor (CHRM2) gene and AD [286,287]. In par-
ticular, one haplotype block within the 5'-UTR of CHRM2 may be 
more important for the development of alcoholism than other re-
gions [287]. Thus, an involvement of mAchRs in the neuro-
biological mechanisms of alcoholism could be hypothesized. How-
ever, at present there are no human or animal studies that have in-
vestigated mAchRs as a new potential target for the treatment of 
AD.  
 
 
ACETYLCHOLINESTERASE INHIBITORS  
 A possible role of acetylcholinesterase inhibitors for alcoholism 
has been hypothesized. In fact, cholinesterase inhibitors act on the 
breakdown of the neurotransmitter acetylcholine and prolong ace-
tylcholine retention time in the synaptic cleft and therefore, the 
efficiency of cholinergic neurotransmission at both mAChRs and 
nAChRs [288]. Galantamine, an alkaloid of many plants of the 
Amaryllidaceae family and of various species of narcissus, is a 
reversible acetylcholinesterase inhibitor which also acts as an allos-
teric potentiating ligand at neuronal nAChRs, especially at the ?7 
and ?4?2 nAChRs, but not at mAChRs [289]. Opitz [290] first 
described a role of galantamine in reducing ethanol preference in an 
animal model of AD. After oral administration of galantamine at 
doses of 5 or 10 mg/kg, in the following 1-2 h exposition time both 
alcohol preference and ethanol intake were reduced significantly. 
Galantamine reduced alcohol intake without decreasing food con-
sumption and total fluid intake. Subsequently, galantamine has also 
shown to improve the speed of learning, short-term memory and 
spatial orientation in rats after prolonged (16 weeks) alcohol intake 
[291]. This last observation is consistent with the hypothesis that 
prolonged alcohol intake could lead to an acetylcholine deficit and 
to an impairment of many brain functions. 
 More recently, the effects of galantamine on voluntary ethanol 
consumption were investigated in female Alko alcohol rats, in 
combination with desoxypeganine, an alkaloid derived from 
Peganum harmala. In this experiment, desoxypeganine, initially 
administered reduced ethanol intake and ethanol preference and 
these effects were dose-dependent, at a dose ranged between 10 and 
30 mg/kg body weight. In this preclinical study, the combination of 
desoxypeganine and galantamine in doses which were ineffective 
when administered alone, caused a significant decrease of ethanol 
preference in rats, suggesting an addictive effect [292].  
 Based on the preclinical studies, Mann and colleagues [293] 
investigated the efficacy of galantamine in prolonging abstinence in 
recently detoxified alcoholics. A 24-week, randomized, placebo-
controlled, multicenter clinical trial involving 149 recently detoxi-
fied alcohol dependent patients was conducted. Galantamine at the 
dose of 25 mg/d or placebo were administered by a patch that was 
renewed every morning during the first 12 weeks (treatment phase), 
then no patch was applied during the successive 12-week period 
(follow-up phase). Patients also received a low-intensity psychoso-
cial standard therapy at each visit. Results of the study showed that 
galantamine, compared to placebo, did not extend the time to first 
severe relapse. Moreover, at the end of the 12-week treatment pe-
riod, significantly fewer patients assigned to galantamine remained 
abstinent (20%) compared to placebo group (41%). The same re-
sults were observed at the end of the follow-up period (week 24). 
The contradictory findings, between preclinical and clinical obser-
vations, could be explained by the different way galantamine was 
administered. Compared with oral administration, the patch offers a 
very different pharmacokinetic profile and probably, the applied 
dose of 25 mg/d was not sufficient to achieve effective plasma lev-
els of the drug. In fact, the average plasma concentration of galan-
tamine was 7.1 ± 9.1 ng/ml, lower than the expected 16.7 ± 9.35 
ng/ml [293]. Another explanation, provided by the authors, is re-
lated to the rapid eye movement (REM). REM pressure during 
sleep is dependent on the central cholinergic system and rises with 
increased cholinergic activity [294]. In turn, the increased REM 
sleep induced by galantamine in alcohol dependent patients after 
alcohol withdrawal represents a robust predictor of vulnerability to 
relapse [294]. Therefore, it might be possible that an increased 
REM induced by galantamine induced the recently detoxified alco-
holics to relapse [293]. Nevertheless, further studies are needed to 
explore if galantamine represents a potential treatment for AD. 
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GLYCINE REUPTAKE INHIBITORS 
 Ethanol administration is known to increase DA output in the 
NAc of the rats [295] as well as in humans [2], and this increase has 
been hypothesized to be of importance for the development of AD 
[296]. The mechanisms by which DA participates in alcohol-
seeking behaviour and how the mesolimbic DA activity is regulated 
have been extensively investigated. Recently, glycine and strych-
nine-sensitive glycine receptors (GlyRs) generated interest in the 
field of AD, considering their involvement in the DA activity. 
 Glycine is the major inhibitory neurotransmitter in the spinal 
cord and brain stem and it has been implicated in controlling neu-
ronal excitability and psychotic symptoms [297]. Glycine receptors 
have also been identified in the CNS and they are expressed on both 
dopaminergic and non-dopaminergic cells of the VTA [298]. Gly-
cine activates GlyRs and determines a reduction of inhibitory 
GABAergic inputs to VTA dopaminergic neurons, producing an 
increase in accumbal DA release [298]. In vitro studies showed that 
ethanol potentiates glycine receptor function [299,300]. Succes-
sively, Molander and Soderpalm [301,302] demonstrated that 
GlyRs are expressed in the rat NAc and that activation of these 
receptors might constitute a priming mechanism for ethanol-
induced enhancement of accumbal DA activity. In particular, a 
local perfusion of strychnine, a GlyR antagonist, decreases accum-
bal DA levels per se and completely prevents the increase of ac-
cumbal DA levels after both local and systemic ethanol administra-
tion. Instead, accumbal perfusion of the GlyR agonist glycine in-
creases DA levels in a subpopulation of rats and prevents the etha-
nol-induced increase after local but not systemic ethanol in all ani-
mals [302]. The same authors also investigated the role of accumbal 
GlyRs in the regulation of voluntary ethanol intake in the rats and 
found that glycine and strychnine altered extracellular DA levels in 
the NAc, probably via GlyR stimulation and blockade, respectively 
[303]. Concomitantly, strychnine and glycine reciprocally altered 
ethanol consumption in ethanol high-preferring rats, respectively 
decreasing and increasing ethanol intake [303]. Thus, results of 
these experiments suggest that GlyRs agonists and/or antagonists 
could represent interesting new ways to treat alcohol dependence.  
 Other research has focused on the possible role of glycine 
transporter (GlyT) inhibitors in voluntary alcohol consumption. 
GlyT proteins are involved in the reuptake of glycine into presynap-
tic nerve terminals and glial processes, allowing the return of ex-
tracellular levels of glycine to basal values. There are two known 
types of GlyT proteins, the GlyT1 and the GlyT2 located on glia 
cells and glycinergic neurons, respectively. The GlyT1 catalyses the 
removal of glycine from the synaptic cleft and the GlyT2 is in-
volved in the reuptake and reloading of glycine into synaptic vesi-
cles [304]. Molander and colleagues [304] investigated the role of a 
selective glycine reuptake inhibitor (Org 25935) in decreasing alco-
hol intake and preference in rats. Org 25935 easily passes the 
blood-brain barrier and acts mainly on the GlyT1 protein. Ge et al. 
[305] administered Org 25935 via i.p. to male Wistar rats with an 
ethanol preference > 60% (during continuous access to a bottle of 
alcohol, 6% v/v, and a bottle of water) and to rats with an ethanol 
preference < 60%. Org 25935 was effective in reducing alcohol 
intake in both populations of rats. This effect was dose-dependent, 
developed gradually and was sustained for up to 40 days. Food 
intake was also transiently reduced. The mechanism underlying the 
effects of Org 25935 in reducing alcohol intake is probably repre-
sented by an increase of extracellular glycine levels and a subse-
quent modulatory effect on brain GlyRs. A more recent study inves-
tigated the DA output in the NAc after systemic administration of 
Org 25935 and ethanol [306], that suggests the involvement of the 
glycine/GlyR system in modulating basal accumbal DA levels and 
in the ethanol-induced elevations of DA in the NAc. Based on these 
studies, it was supposed that the anti-alcohol effect of Org 25935 is 
due to i) a substitution mechanism by stimulation of GlyRs and 
elevation of DA levels; and ii) antagonism mechanism by preven-
tion of further GlyR activation and DA elevation by ethanol. 
 Based on this first preclinical evidence, a double-blind, pla-
cebo-controlled clinical trial is currently investigating the safety, 
tolerability and efficacy of Org 25935 on alcohol-dependent indi-
viduals (NCT00764660).  
ALPHA-ADRENERGIC RECEPTOR 
 Norepinephrine in the limbic system is important to emotional 
learning and may be involved in the neuroadaptations that lead to 
the development of dependence. In the amygdala, increased 
norepinephrine (NE) activity leads to creation of stronger and 
longer-lasting memories [307]. NE depletion produced by blockade 
of the synthetic pathway attenuates ethanol-self administration in 
rats [308]. Ligands targeting different receptor subtypes of the NE 
system have been most extensively studied for reducing certain 
aspects of ethanol withdrawal symptomology. In particular, it has 
been shown that ?-adrenergic antagonists and ?2-noradrenergic 
receptor agonists appear to be efficacious in reducing withdrawal 
symptoms and ?1-noradrenergic receptor antagonists in reducing 
locomotor hyperactivity produced by ethanol withdrawal [309].  
 Though early work suggested that the NE reuptake inhibitor 
desipramine prolonged the time to relapse in depressed alcoholics 
[310,311], research on alcohol pharmacotherapy has been slow to 
focus on the NE system. Recently, this interest has been renewed. 
Initially, research focused on the ?2-adrenoceptor antagonist yo-
himbine, while more recent research is focusing on the prototype 
?1-blocker prazosin. 
 Yohimbine, an ?2-adrenoceptor antagonist which acts by in-
creasing norepinephrine cell firing and norepinephrine release in 
terminal areas, was proposed as an effective drug in the treatment 
of AD [312]. In this study, injections of the ?2-adrenergic receptor 
antagonists, yohimbine and methoxyidazoxan, to rats decreased 
intake of alcoholic beverage and increased intake of water. Fur-
thermore, yohimbine alone persistently reduced intake of alcohol 
with daily administration [312]. However, subsequent studies did 
not confirm these observations. Indeed, it was shown an effect of 
yohimbine in reinstating alcohol seeking both in rats and in humans 
probably by inducing anxiety- and stress-like response and acting as 
a pharmacological stressor [313]. 
 Prazosin, an ?1-noradrenergic receptor antagonist, has aroused 
interest as effective drug in reducing alcohol intake. Prazosin was 
evaluated for the ability to modulate operant ethanol self-
administration in non-dependent and ethanol-dependent animals 
during acute withdrawal [309]. In this study, prazosin at different 
dosages (0.0, 0.25, 1, 1.5 and 2 mg/kg) was administered to ethanol 
dependent and control rats during acute withdrawal. Prazosin re-
duced self-administration of ethanol in both non-dependent and 
ethanol-dependent rats during acute withdrawal. However, prazosin 
was more potent in ethanol-dependent animals, suggesting an in-
crease in the sensitivity to prazosin in dependent animals due to 
alterations in the norepinephrine system during chronic exposure to 
ethanol. Then, Rasmussen and colleagues [314] tested the efficacy 
of prazosin in suppressing alcohol drinking in rats selectively bred 
for alcohol preference (P line). Adult male P rats were given open 
access to food and water and scheduled access to a 15% (v/v) alco-
hol solution for 2 hours daily. Prazosin at different doses (0, 0.5, 
1.0, 1.5, or 2.0 mg/kg body weight) was injected i.p., once a day 
prior to onset of the daily 2-bottle choice (alcohol vs. water), for 3 
weeks. Prazosin significantly reduced alcohol intake during the 
initial 2 daily administrations, and this reduction of alcohol intake 
was maintained in the subsequent more prolonged trial and was not 
dependent upon drug-induced motor impairment 
 Based on these promising preclinical results, Simpson and col-
leagues [315] tested the effectiveness of prazosin in reducing drink-
ing and craving for alcohol among AD patients. Twenty-four alco-
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hol-dependent patients were randomized to receive either prazosin 
or placebo in a 6-week, double-blind pilot study. Medication was 
titrated to a target dose of 4 mg QAM, 4 mg QPM, and 8 mg QHS 
by the end of week 2. Results of the study showed fewer drinking 
days and drinks per week in the prazosin group with respect the 
placebo group during the final 3 weeks of the study. With regard to 
craving, although the entire sample on average reported signifi-
cantly decreased craving from baseline to the final assessment, the 
prazosin group did not report significantly less craving than the 
placebo group. No significant side-effects were reported, although 
one of the prazosin-treated participants experienced syncope, re-
quiring a dose reduction. At present, large controlled studies are in 
progress to further investigate the role of prazosin in AD (e.g. 
NCT00762710). 
CALCIUM-ACTIVATED-POTASSIUM (CAK) CHANNELS  
 In CNS neurons, calcium-activated-potassium (CAK) channels 
modulate neuronal activity by controlling intrinsic excitability, 
tonic firing frequency, spike frequency adaptations, and action po-
tential repolarization. These channels are activated by elevations in 
intracellular Ca2+ that occurs during single or trains of action po-
tentials, and their activation is thought to contribute to the pro-
longed after hyperpolarization that follows an action potential. 
 CAK channels are defined by two phenotypic characteristics: 
their pores conduct K+ rather selectively over other monovalent 
ions, and their steady-state activity is enhanced by increases in in-
tracellular calcium. Based on their K+ permeability, three types of 
CAK channels have been recognized and they demonstrate hetero-
geneous pharmacological and kinetic properties: small (SK), inter-
mediate (IK) and large conductance (BK or MaxiK) [316,317]. SK 
and BK have been more extensively studied in alcohol dependence. 
 SK channels underlie the medium phase of the hyperpolariza-
tion and are important for shaping postsynaptic responses and con-
trolling intrinsic excitability, dendritic integration, and pacemaker 
firing. 
 The spontaneous action potential of VTA neurons is determined 
by a number of voltage and Ca2+-dependent currents, which in-
volve SK channels [318]. Since ethanol directly excites DA VTA 
neurons [319], a recent study addressed the possibility that repeated 
ethanol exposure and withdrawal leads to altered firing properties 
of VTA DA neurons through changes in SK channel function [320]. 
Specifically, Hopf and colleagues [320] used ex vivo brain slice 
electrophysiology to characterize whether pacemaker firing and 
NMDA-induced burst firing in VTA neurons were altered after 5 
days of intermittent ethanol exposure and 7 days of withdrawal, and 
what channels might be altered functionally to explain any observed 
firing differences. This study demonstrated that repeated ethanol 
and withdrawal leads to a significant reduction in VTA SK currents 
[320]. Thus, SK channels are a critical component of the VTA neu-
ronal membrane conductance and play an important role in DA 
VTA neurons, i.e. altering the responsiveness of these neurons to 
external stimulation, either by endogenous agents, like neurotrans-
mitters, or by exogenous agents, like alcohol.  
 Other studies showed that the excitatory effects of ethanol can 
be modulated by a number of agents that block SK channels or 
affect Ca2+ levels and release [318]. Moreover, manipulation of 
Ca2+ i levels and release can result in reduction of overall Ca2+i, 
and, as a direct antagonism of SK, these manipulations can increase 
the excitatory action of ethanol [321]. Finally, a recent study has 
shown an association between reduced small-conductance calcium-
activated potassium channel (SK) currents and increased firing in 
the NAc core after protracted abstinence from alcohol but not su-
crose self-administration [322]. In conclusion, consistent with evi-
dence of an interaction between ethanol and SK currents in reward 
neurons of the VTA, SK channels may represent a novel target to 
treat AD. 
 The BK channels are largely expressed in the brain and contrib-
ute to the fast phase of the AHP. These channels play an essential 
role in many aspects of neuronal physiology, including neurotrans-
mitter release, action potential patterning and dendritic excitability. 
In addition, a number of studies have also implicated an important 
role for BK channels in ethanol tolerance and adaptive plasticity 
[317-323]. 
 The BK channel is composed of a primary protein, containing a 
pore that acts as a conduit for K+ ions. This primary protein is often 
combined with a variety of auxiliary proteins (b1-b4) that modify 
the function of the channel, including alcohol sensitivity. Com-
partment-specific expression of b subunits of the BK channels has 
been proposed to explain differences in BK-related alcohol sensitiv-
ity between the somatic, dendritic and terminal compartments of 
neurons [324]. One of these auxiliary proteins, known as b4, plays a 
key role in acute alcohol tolerance. In fact, an experiment with mice 
knocked out for the gene encoding the b4 subunit [325] showed that 
the b4 subunit inhibits acute alcohol tolerance and the presence of 
acute tolerance is an indicator of alcohol consumption.  
 There is also evidence that lipid composition of biological 
membranes is altered differently by acute and chronic alcohol expo-
sure as experiments with BK channels provide evidence of the 
powerful effects that lipid environment can have in both the imme-
diate and adaptive response to alcohol, considering that BK might 
move into and out of lipid rafts, thereby changing both the acute 
response and adaptation to alcohol [326,327].  
VOLTAGE-GATED CALCIUM CHANNELS 
 Voltage-gated calcium channels (VGCCs) are multimeric pro-
tein complexes that mediate Ca2+ entry into neurons in response to 
changes in membrane potential and regulate neuronal excitability, 
neurotransmitter release, and gene expression. They are classified 
according to their electrophysiological and pharmacological proper-
ties [328]. High voltage-activated N-type calcium channels are 
exclusively expressed in the nervous system, where they contribute 
to neurotransmitter release at a subset of central and peripheral 
nerve terminals [329]. Low voltage-activated T-type calcium chan-
nels are biophysically distinct from N-type channels and contribute 
to rhythmic firing and bursting behaviours related to processes such 
as sleep and epileptiform activity [330]. 
 Acute ethanol exposure inhibits N-type calcium channels, and 
chronic ethanol exposure increases N-type channel function and 
density. Ethanol appears to have complex effects on T-type cur-
rents. In slices from the lateral geniculate nucleus, low concentra-
tions of ethanol potentiate T-type currents, whereas higher ethanol 
concentrations inhibit T-type currents [331]. The principal defined 
role for N-type calcium channels is the regulation of evoked neuro-
transmitter release [332].  
 Newton et al. [333] chose a genetic approach by studying etha-
nol responses in mice that carry a null mutation in the calcium 
channel subunit Cav2.2 and therefore lack functional N-type cal-
cium channels. In these animals, voluntary ethanol consumption is 
reduced and place preference is developed only at a low dose of 
ethanol. The hypnotic effects of ethanol are also substantially di-
minuished, whereas ethanol-induced ataxia is mildly increased. 
These results demonstrate that N-type calcium channels modulate 
acute responses to ethanol and are important mediators of ethanol 
reward and preference [333]. 
 The same group tested the effect of a novel mixed inhibitor of 
N-type and T-type calcium channels, 1-(6,6-bis(4-fluorophenyl) 
hexyl)-4-(3,4,5- trimethoxybenzyl) piperazine (NP078585) in ani-
mal model of ethanol intoxication, reinforcement, reward, and rein-
statement. The results of these studies showed that NP078585 re-
duced the acute effects of ethanol and abolished the expression of 
ethanol conditioned place preference in mice [334] supporting the 
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hypothesis that N-type calcium channels contribute to ethanol in-
toxication, reinforcement, reward, and reinstatement. 
 Considering that N-type calcium channel inhibitors are being 
developed for clinical use, these data show the possibility that AD 
individuals treated with N-type or mixed N- and T-type calcium 
channel inhibitors may become less motivated to experience the 
effects of ethanol.  
SIGMA-RECEPTORS (SigRs) 
 Sigma receptors (SigRs) were originally called as sigma/opioid 
receptors because the effect of the prototypic sigma/opioid receptor 
ligand, N-allylnormetazocine, was reported to be antagonized by 
the opioid antagonist naloxone [335]. At least two subtypes of 
sigma receptors, SigR1 and SigR2, are known. 
 Because SigR1s are involved in regulating dopaminergic, 
NMDA and glutamatergic neurotransmission in limbic areas, in-
cluding the NAc and the VTA a role of SigR1 in development of 
AD has been hypothesized. Miyatake and colleagues [336] per-
formed a functional analysis of polymorphisms in the SigR1 and a 
case-control study, involving 307 alcoholic and 302 control sub-
jects. These investigators not only identified the novel T-485A 
polymorphism, but also found that the transcriptional activity of the 
A-485 allele and the TT-241-240 allele was significantly reduced 
compared with that of the T-485 allele and the GC-241-240 allele. 
Moreover, the frequencies of the A-485 allele and the TT-241-
240/Pro2 haplotype were significantly higher in control subjects 
compared with alcoholic subjects, suggesting a possible protective 
role for the development of alcoholism [336]. 
 More recently, a role of SigR antagonists in modulating etha-
nol’s actions has been proposed. A recent study investigated the 
effects of subcutaneous treatment with the potent, selective SigR1 
antagonist BD-1063 on operant ethanol self-administration in two 
models of excessive drinking (Sardinian alcohol-preferring (sP) rats 
and ethanol-dependent Wistar rats), compared to non-dependent 
Wistar controls [337]. BD-1063 dose-dependently and selectively 
reduced oral ethanol self-administration in sP rats and in ethanol 
dependent Wistar rat. Moreover, BD-1063 reduced the motivation 
of sP rats to work to obtain alcohol. A significant decrease of SigR1 
mRNA expression in the NAc was found in both ethanol-naïve sP 
rats and ethanol-dependent Wistar rats with respect to ethanol-naïve 
control Wistar rats, suggesting a role of SigR1s in the modulation 
of excessive ethanol intake and reinforcement and a role of SigR1s 
antagonists as potential target for medication development for 
treatment of alcoholism [337]. Further confirming preclinical stud-
ies and exploratory human studies are needed to confirm this initial 
evidence. 
MELANOCYTE STIMULATING HORMONE (MSH) 
 A role for melanocortins (MC) peptides in neurobiological re-
sponses to drugs of abuse has been established. The MC system is 
composed of peptides that are cleaved from the polypeptide precur-
sor, proopiomelanocortin (POMC), which is also the precursor for 
?-endorphin. These peptides include adrenocorticotropic hormone 
(ACTH), ?-melanocyte stimulating hormone (?-MSH), ?-MSH, and 
?-MSH [338]. The production of these peptides occurs in the neu-
rons within the hypothalamic arcuate nucleus, the nucleus of the 
solitary tract, and the medulla. At least five subtypes of MC pep-
tides receptors, including MC4R, have been identified [338], which 
have been implicated in most behavioural effects including neuro-
biology of depression [339].  
 An involvement of MC signalling in AD has been suggested. In 
order to investigate the involvement of the MCs in AD, Ploj and 
colleagues [340] analysed the effects of the MC4R antagonist 
HS014 (1 nmol/rat), and the non-selective MC-receptor agonist 
MTII (1 nmol/rat), administered i.c.v., on ethanol intake in alcohol-
preferring AA rats. MTII caused a reduction in ethanol intake and 
ethanol preference, whereas HS014 had no any effect. Simultane-
ously, MTII and HS014 altered opioid peptide levels in several 
brain areas and in the pituitary gland of alcohol-preferring AA rats 
the rats.  
 Navarro and colleagues [341] extended the previous findings 
[340] by showing that both central and peripheral administration of 
MTII reduces ethanol drinking. Subsequently, the same group dem-
onstrated that an i.c.v. infusion of the highly selective MC4R ago-
nist cyclo (NH-CH2-CH2-CO-His-d-Phe-Arg-Trp-Glu)-NH2 at 
doses of 1.0 or 3.0 microg significantly reduced ethanol drinking in 
rats [342]. In a more recent study, the role of ?-MSH in mediating 
the acute and chronic effects of ethanol and withdrawal-related 
depression was investigated in rats [338]. Results of the study 
showed that ?-MSH may be closely involved in mediating the ac-
tions of ethanol and that the nature of interaction may be dictated 
by the protocol of ethanol treatment. Central administration of ?-
MSH (100 ng/rat, i.c.v.) was found to suppress the anti-immobility 
effect of acute ethanol, while HS014 (0.01 ng/rat, i.c.v.) was found 
to enhance. Chronic ethanol exposure resulted in increased immo-
bility time, while further augmentation in immobility was noticed 
following ethanol withdrawal. However, concomitant HS014 (0.01 
ng/rat, icv) treatment prevented tolerance as well as attenuated en-
hanced immobility in ethanol-withdrawn rats. In brief, while 
acutely administered ethanol causes antidepressant-like effect and 
may trigger antagonistic homeostatic response from the ?-MSH, 
chronic ethanol treatment results in the up-regulation of the entire 
?-MSH system that may contribute to the tolerance.  
 The present data support the hypothesis that the endogenous 
MC system modulates neurobiologic responses to ethanol. Thus, 
compounds that target MCRs may a have therapeutic value in the 
treatment of excessive ethanol consumption and/or the symptoms 
associated with ethanol withdrawal. 
VASOPRESSIN 
 A growing body of evidence suggests that vasopressinergic 
neuronal activity in the amygdala and PVN of the hypothalamus 
represents an important element in the neurobiology of stress-
related behaviours. In fact, acute stress increases extracellular levels 
of arginine vasopressin (AVP) in the rat amygdala and hypothala-
mus [343,344], and activation of AVP-receptors modulates anxio-
genic and depressive behaviours in rats [344]. Vasopressin binds to 
three different G protein-coupled receptor subtypes: V1a, V1b, and 
V2. The V2 receptor is expressed almost exclusively in the kidney. 
The V1a and V1b receptors are localized in the brain, and the dis-
tribution of vasopressin receptor binding is prominent in the rat 
extended amygdala, with high concentrations in the lateral and 
supracapsular bed nucleus of the stria terminalis, the central nucleus 
of the amygdala, and the shell of the NAc [345]. 
 Prolonged or chronic ethanol exposure decreases vasopressin-
like immunoreactivity in the hypothalamus and the bed nucleus of 
the stria terminalis projection to the lateral septum [346]. A selec-
tive V1b receptor antagonist dose-dependently blocks the increase 
in ethanol self-administration during withdrawal in dependent rats 
but has no effect in nondependent animals [347]. To date, few stud-
ies have explored the motivational effects of vasopressin antago-
nists in animal models of dependence or stress-induced reinstate-
ment with other drugs of abuse. However, the literature suggesting 
that V1b antagonists have anxiolytic like profiles and that vaso-
pressin and its receptors are highly expressed in the extended 
amygdala lead to hypothesize that the vasopressin system may have 
a role in the increased alcohol intake associated with dependence 
[347]. 
LUTEINIZING HORMONE (LH) 
 Hypothalamic luteinizing hormone releasing hormone (LHRH) 
neurons are projected to some of the brain regions implicated in the 
regulation of behaviour including the NAc and VTA. This may 
explain why LHRH analogues may exhibit a variety of effects such 
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as antidepressant, anti-anxiety, analgesic, anticonvulsant, catalepsy, 
drug discrimination learning, and inhibition of condition avoidance 
response [348]. LHRH also modulates the activity of serotonin, 
glutamate, DA and opioids. A recent study showed that the LHRH 
agonist leuprolide exhibits an anticompulsive-like effect, and also 
mediates the anticompulsive effect of fluoxetine [349]. In view of 
the evidence that ethanol administration to rats reduces hypotha-
lamic content of LHRH, suppresses LHRH secretion, reduces 
LHRH mRNA levels and inhibits LHRH binding to its receptor, it 
was speculated that ethanol dependence and withdrawal syndrome 
may be related to changes in the LHRH system [348]. In this con-
nection, the effects of the LHRH agonist leuprolide on ethanol de-
pendence were investigated in animals [348]. Since leuprolide 
modulates sex hormones levels, which are reported to influence 
behaviour, the studies were also carried out in castrated state.  
 The results of this study suggested that acute administration of 
leuprolide attenuated the expression of ethanol withdrawal behav-
iour, whereas on chronic administration, it attenuated the develop-
ment of AD, representing a potential new target.  
STEROID BIOSYNTHESIS 
 Peripheral neuroactive steroids can act in the CNS as allosteric 
modulators of neurotransmitter receptors, such as GABA, NMDA, 
and sigma receptors. For instance, the progesterone metabolites 
allopregnanolone (ALLO), Tetrahydrodeoxycorticosterone (THD-
OC), and pregnanolone act as potent positive allosteric modulators 
at the GABA-A receptor [350]. Endogenous steroids have anx-
iolytic, anticonvulsant, analgesic and hypnotic properties, and also 
attenuate stress responses mediated by the HPA axis [351]. 
 Some studies have shown that ethanol intake produces an eleva-
tion in both brain ALLO concentrations [352] and in plasma ALLO 
levels [353], in animals and humans, respectively. Furthermore, 
exogenous ALLO application stimulated limited-access ethanol 
drinking in male mice [354]. Moreover, administration of the 5-
alfa-reductase inhibitor finasteride (FIN), which decreases endoge-
nous levels of ALLO, significantly altered ethanol drinking. In 
particular, subchronic FIN treatment (7 days) significantly attenu-
ated limited access ethanol preference drinking in male C57BL⁄ 6J 
mice [355]. Similar modifications were also observed in humans, 
where acute administration of FIN induces changes in both subjec-
tive states and neuroactive steroid concentration [356]. The ob-
served correlations between the subjective and endocrine measures 
provide preliminary support for a role of these endogenous steroids 
in some of the subjective effects of alcohol. 
 In a recent work Ford et al. [357] hypothesized that inhibition 
of 5a-reduced neurosteroid biosynthesis would hinder the acquisi-
tion of ethanol intake, presumably by attenuating positive modula-
tory tone at GABA-A receptors. Thus, these investigators examined 
the effect of subchronic FIN administration on the acquisition of 
limited access ethanol preference drinking in male B6 mice. They 
found that FIN dose-dependently blocked the acquisition of drink-
ing and prevented the development of ethanol preference, thereby 
suggesting that the GABAergic neurosteroids may be important in 
the establishment of stable drinking patterns. FIN-treated mice con-
tinued to exhibit attenuated ethanol consumption after 2 weeks 
post-treatment, despite a full recovery in brain ALLO levels. This 
study suggests that FIN-mediated modulation of the GABAergic 
system may be useful in curbing ethanol intake acquisition [357]. 
IS THERE A PLACE FOR NON-PHARMACOLOGICAL 
NEUROBIOLOGICAL APPROACHES? 
 Although beyond the goals of this review, we want to mention 
the recent and growing interest for some techniques, such as the 
transcranial magnetic stimulation (TMS). In fact, “boosting” the 
DA system should ameliorate compulsive drug/alcohol use [358], 
and this is the principle how TMS might work alcohol consump-
tion. Transcranial magnetic stimulation is the first non-invasive 
non-pharmacological therapeutic approach to mental/brain disor-
ders [359]. As such TMS promises to be an innovative approach to 
alcohol and other addictions with a negligible range of systemic 
side-effects and limited contraindications. In particular, recent tech-
nological developments such as the H-coil [360] allow modulation 
of brain regions as deep as 6 cm below cortical surface [360] 
thereby making the NAc accessible to external modulation. 
CONCLUSIONS 
 This review has presented and discussed a variety of studies 
that have investigated possible new targets in the treatment of AD. 
These studies demonstrate a growing scientific excitement and 
complexity aimed at finding new pharmacotherapies for AD. Alco-
hol dependence is now considered a medical disease, but unlike 
other medical problems (hypertension, diabetes, just to cite few), 
only a few medications are available. Thus, there is a crucial need 
to develop new more effective pharmacotherapies for the treatment 
of AD patients. Future research will aim to translate the present 
data into clinical settings. However, translating preclinical into 
clinical success has its own challenges as we note that in some in-
stances there is discordance between animal and human studies. 
Additionally there is a need to identify specific typologies of alco-
holics who may benefit from specific pharmacotherapies [361]. In 
summary, future research must seek to identify not only efficacious 
medications, but also - and more importantly - to delineate the best 
match between a particular pharmacotherapy and a specific alco-
holic typology. 
ABBREVIATIONS 
?CtxMII = ?-conotoxin MII 
18-MC = 18-Methoxycoronaridine 
ACD = Acetaldehyde 
Ach = Nicotinic acetylcholine 
ACTH = Adrenocorticotropic hormone 
AD = Alcohol dependence 
ADH = Alcohol dehydrogenase 
ALDH-2 = Aldehyde dehydrogenase 2 
ALLO = Allopregnanolone 
AMPA = Methylisoxazole-4-propionic acid 
ARC = Arcuate nucleus 
AVP = Arginine vasopressin 
BK or MaxiK = Large conductance 
Ca
+2
 = Calcium 
CAK = Calcium-activated-potassium 
CB = Cannabinoid 
CeA = Central nucleus of amygdala 
CFH = Corticotropin-releasing hormone 
CHRM2 = Muscarinic acetylcholine M2 receptor 
CNS = Central nervous system 
COGA = Collaborative Study on the Genetics of  
Alcoholism 
CPP = Conditioned place preference 
CRF = Corticotropin-releasing factor 
CRFR = Corticotropin-releasing factor receptor 
CYP2E1 = Cytochrome P4502E1 
DA = Dopamine 
DH?E = Dihydro- ?-erythroidine  
DR = Dorsal raphe 
FDA = Food and Drug Administration 
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FIN = Finasteride 
GABA = ?-aminobutyric acid 
GalR = Galanin receptor 
GDNF = Glial cell line-derived neurotrophic factor 
GH = Growth hormone 
GHS-R = Growth hormone secretagogue receptor 
GlyR = Glycine receptor  
GlyT = Glycine transporter 
HPA = Hypothalamic-pituitary axis 
i.c.v.  = Intracerebroventricular 
i.p.  = Intraperitoneally 
iGluR = Ionotropic glutamate receptor 
IK = Intermediate conductance 
ITF = Inducible transcription factor 
K
+
 = Potassium 
KA = Kainic acid 
LaH = Lateral hypothalamus 
LC = Locus coeruleus 
LDTg = Laterodorsal tegmental nucleus 
LH = Luteinizing hormone 
LHRH = Luteinizing hormone releasing hormone 
LS = Lateral septum 
mAchR = Muscarinic acetylcholine receptor 
MC = Melanocortins 
MeA = Medial nucleus of amygdala 
mGluR = Metabotropic glutamate receptor 
MLA = Methyllycaconitine 
MPEP = 2-Methyl-6-(phenylethynyl)-pyridine 
MPZP = (N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-
methylphenyl)-2,5-dimethylpyrazolo[ 
1,5a]pyrimidin-7-amine) 
MSH = Melanocyte stimulating hormone 
MSH = Melanocyte stimulating hormone 
MTEP = 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-
pyridine 
MTIP = 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-
(1-ethylpropyl)- 2,6-dimethyl-imidazo[1,2-
b]pyridazine 
N/OFQ = Nociceptin/Orphanin FQ 
NAc = Nucleus accumbens 
nAchR = Nicotinic acetylcholine receptor 
NAM = Negative allosteric modulator 
NE = Norepinephrine 
NE = Norepinephrine system 
NK1R = Neurokinin 1 receptor 
NK3R = Tachykinin receptor 3 
NMDA = N-methyl-D-aspartic acid 
NOP = Nociceptin/orphanin peptide 
NP078585 = 1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,4,5- 
trimethoxybenzyl) piperazine 
npEW = Non-preganglionic Edinger-Westphal 
NPS = Neuropeptide S 
NPY = Neuropeptide Y 
ORL-1 = Opioid receptor-like 1 
pIIIu = Perioculomotor urocortin 
POMC = Proopiomelanocortin 
PTSD = Posttraumatic Stress Disorder 
PVN = Paraventricular nucleus 
REM = Rapid eye movement 
Ret = Transfection receptor 
SigR = Sigma-receptor 
SK = Small conductance 
SNc = Substantia nigra pars compacta 
SP = Substance P 
STAI = Spielberg Trait Anxiety Inventory Test 
TH = Tyrosine hydroxylase 
THDOC = Tetrahydrodeoxycorticosterone 
TMS = Transcranial magnetic stimulation 
Ucn = Urocortin 
US = United States 
VGCC = Voltage-gated calcium channels  
VTA = Ventral tegmental area 
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